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Summary 
Total joint replacements are highly successful in relieving pain and restoring movement of 
damaged joints. However, the lifespan of the implants is limited. The implant’s long-term 
stability depends largely on the preservation of periprosthetic bone. Debris-wear particulates 
were first identified as the factor inducing periprosthetic bone loss. However, it was shown 
later that the resorption process starts before the particulates reach the periprosthetic bone. 
Thus a mechanical factor, interface micromotions, has been suspected to be the initiator of 
early bone loss.  
In the first part of this thesis, we investigated the response of bone cells to micromotions. 
Using an ex vivo setup, we applied micromotions on fresh human bone cores and showed that 
micromotions could indirectly activate osteoclasts after only 1 hour. Thus micromotion-
related osteoclastic activity could be the initiator of periprosthetic bone loss. Local release of 
bisphosphonate seemed therefore to be an ideal solution to prevent early bone loss, as the 
target is a local process.  
The few previous studies assessing local release of bisphosphonate in vivo reported increased 
periprosthetic bone stock and/or strengthen implant fixation. But these studies only concerned 
rats and were designed empirically. In the second part of the thesis, to overcome the limitation 
resulting from the sole usage of rats, we performed a study of local zoledronate release in 
sheep trabecular bone. We measured that, at 4 weeks post-operatively, periprosthetic bone 
was 50% denser with zoledronate than without.  
To further analyze these experimental results, a theoretical model of bone adaptation with 
bisphosphonate was developed. This new model updated an existing mechanically-driven 
bone adaptation model by adding an equation of drug-driven bone adaptation. The 
identification of the model parameters was carried-out with the existing experimental data. 
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Based on the new model, the dose of zoledronate that would maximize the periprosthetic bone 
density was calculated; this dose was then tested in vivo and the results validated the model’s 
prediction with a good accuracy. 
The fundamental assumption in the theoretical model was that the mechanical stimulus and 
the drug stimulus were independent. The last aim of the thesis was then to verify this 
assumption. We investigated potential interactions between mechanical effects and 
bisphosphonate on bone adaptation in a model of adaptation of the mouse tibia to axial 
compression, combined with systemic injections of zoledronate. We observed that the effects 
of each stimulus were independent in general, however in very high strain conditions, 
zoledronate seemed to reduce the bone response to mechanical stimulation.  
On a clinical perspective, the major results of the thesis were, first, that local micromotions 
can initiate periprosthetic bone resorption rapidly and thus favor aseptic loosening on long-
term. This new data provides a strong rationale for the local use of bisphosphonate rather than 
systemic. The second major result was the demonstration that local release of zoledronate 
increases periprosthetic bone stock in sheep. Finally, the new theoretical model is a 
convenient tool to plan clinical studies and compare experimental results.  
 
Keywords:  
Micromotions; periprosthetic bone loss; bisphosphonate; local delivery; orthopedic implants; 
in vivo mechanical loading; bone adaptation; theoretical model.  
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Résumé 
Les arthroplasties totales réussissent avec succès à soulager la douleur et à rendre leur 
mobilité aux articulations endommagées, mais la durée de vie des implants est limitée. La 
stabilité à long terme des implants dépend surtout de la préservation de l'os périprosthétique. 
Les particules d’usure des composants prosthétiques ont été les premiers facteurs identifiés 
comme induisant une perte osseuse. Cependant, la résorption peut survenir avant que des 
débris n’apparaissent dans la zone périprosthétique. On suppose donc que la résorption puisse 
être initiée par un facteur mécanique : les micromouvements à l’interface os-implant. Dans la 
première partie de cette thèse, nous avons étudié la réponse des cellules osseuses aux 
micromouvements. Dans un système ex-vivo, nous avons appliqué des micromouvements sur 
des échantillons d’os humains fraîchement disséqués et nous avons observé que les 
micromouvements peuvent indirectement activer les ostéoclastes en seulement 1 heure. 
L’activité des ostéoclastes liée micromouvements pourrait donc être à l’origine de la perte 
osseuse périprosthétique. La libération locale de bisphosphonate semble alors être une 
solution idéale pour prévenir l’ostéolyse périprosthétique, qui est un processus local. Les 
études précédentes évaluant l’usage local de bisphosphonate ont rapporté une densité osseuse 
accrue et/ou un renforcement de la fixation des implants dans l’os. Mais ces études ne 
concernaient que des rats et avaient été conçues de manière plutôt empirique. Dans la 
deuxième partie de la thèse, pour surmonter la limitation résultante du seul usage des rats, 
nous avons réalisé une étude de libération locale de zoledronate chez le mouton. Nous avons 
mesuré que, après à 4 semaines, l'os trabeculaire périprosthétique était 50% plus dense avec 
zoledronate que sans.  
Pour mieux interpréter les données expérimentales, un modèle théorique de l'adaptation 
osseuse en présence de bisphosphonate a été développé en se basant sur un modèle mécanique 
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d'adaptation auquel on a ajouté une équation de l’effet du bisphosphonate. Les paramètres 
numériques ont été  identifiés à partir des données expérimentales. La dose de zoledronate qui 
maximiserait la densité osseuse périprosthétique a été calculée et une expérience in vivo a 
validé le résultat du modèle avec une bonne précision.  
L’hypothèse fondamentale du modèle était que le stimulus mécanique et le stimulus du 
bisphosphonate étaient indépendants. Le dernier but de la thèse consistait à vérifier cette 
hypothèse. Pour cela, nous avons étudié les interactions entre les effets mécaniques et l’effet 
du bisphosphonate sur l'adaptation osseuse dans un modèle in vivo de compression axiale du 
tibia de souris, combiné avec des injections systémiques de zoledronate. Nous avons observé 
qu’en général les effets étaient indépendants, mais qu’en conditions de contraintes élevées, 
le zoledronate semble diminuer la réponse osseuse aux stimulations mécaniques.  
D’un point de vue clinique, les principaux résultats de la thèse sont, premièrement, que les 
micromouvements locaux induisent rapidement une résorption osseuse et favorisent ainsi le 
descellement aseptique, ce qui justifie l'usage local de bisphosphonate plutôt que systémique. 
Deuxièmement, la libération locale de zoledronate induit une augmentation de la densité 
osseuse chez le mouton. Finalement, le nouveau modèle théorique est un outil pratique pour 
planifier des études cliniques et comparer les résultats expérimentaux. 
 
Mots-clés:  
Micromouvements; Perte osseuse périprosthétique; bisphosphonate; libération locale; 
implants orthopédiques; stimulation mécanique in vivo; adaptation osseuse 
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Introduction 
1 Epidemiology of orthopedic implants  
1.1 The success story of total joint replacement 
Total joint replacement is an effective treatment for relieving pain and restoring function for 
patients with damaged joints. According to the American Academy of Orthopedic Surgeons 
(AAOS)1: 
 
“Total joint replacement is a success story, enabling hundreds of thousands of people to live 
fuller, more active lives. Using metal alloys, high-grade plastics, and polymeric materials, 
orthopedic surgeons can replace a painful, dysfunctional joint with a highly functional, long-
lasting prosthesis. ” 
 
Orthopedic prostheses have been designed to replace damaged joints, such as hips, knees, 
shoulders (Figure 1), elbows, ankles, wrists, etc. Over the past half-century, there have been 
many advances in the design, construction, and surgical implantation of total joint 
replacement, resulting in a high percentage of successful outcomes. For the majority of 
patients, initial results following surgery are excellent. Therefore, joints replacements are 
considered nowadays amongst the most successful surgical procedures.  
 
                                                
1 www.aaos.org 
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Figure 1 - Schemes of knee, hip and shoulder total replacements (source AAOS). 
In the AAOS statistics, total knee replacements and total hips replacements were respectively 
ranked 1st and 3rd in the top five primary procedures for musculoskeletal-related 
hospitalizations. The costs of hospitalization related to joints replacements account for 
billions of dollars each year in the USA only. In 2005, 534’000 total knees, 235’000 total 
hips, 234’000 partial hips and 15’000 total shoulders replacements have been performed in 
the USA. These numbers keep increasing each year, as the population continues to age and as 
the indications for joints replacements extend to younger patients (Figure 2) [1].  
 
Figure 2 - Number of joints replacements in USA between 1991 and 2005 
and associated costs between 1999 and 2003. (Adapted from AAOS) 
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1.2 Complications after total joints replacements 
Implants have limited life span. Numerous revisions are performed. 
Despite the very high rate of successful surgery, joint replacements cannot be expected to last 
for the patient’s lifetime. In reality, they last 10 to 15 years on average. At ten years post-
operatively 15% to 20% of replaced hips have already been revised [1].  
The past years have seen the growing number of joint replacements be followed by a growing 
number of revisions and increasing associated hospitalization costs. In 2005, 35’000 hip 
replacements revisions and 37’000 knee replacements revisions were performed in the USA. 
The total hospitalization costs for these revisions exceeded 3 billions of dollars (Figure 3). As 
younger people are likely to place more demands on their artificial joints as they generally 
live more active lives, the younger a person is at the time of surgery, the more likely is that 
surgery will have to be repeated later in life. The indication of total joint replacement extends 
more and more to young patients and, as a result, the number of revisions will certainly keep 
growing in the future. 
 
Figure 3 - Number of joints implants revisions between 1991 and 2005 
and associated costs between 1999 and 2003. (Adapted from AAOS) 
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Revisions are dangerous 
Revision surgery is difficult to perform and expansive. Clinical outcomes after joint 
replacements revision surgery are less predictable and generally inferior to the outcome after 
primary joint replacements [1]. With each revision surgery, the lifespan of an implant 
decreases. This is one reason why physicians often delay joint replacement surgery as long as 
possible.  
For example, revision of the conventional hip prostheses involves technical difficulties and 
complications such as femoral fractures and postoperative dislocations: Witjes et al. have 
reported that hip revision procedures are associated with a high rate of complications within 2 
years of implantation [2]. In their study, Chen et al. have reported 51% of poor satisfaction in 
a patient survey and that 12% of the hip prosthesis needed revision within 7 years post-
operatively [3].  
 
Reasons for revisions 
There are several major complications of total joint arthroplasties. The most important 
complications are loosening, infections and dislocations. These three reasons account for 
almost 90% of the diagnoses (Figure 4) [1].   
Surgical or long-term infections are the most feared of all the complications in total joint 
arthroplasties. Fortunately, the incidence of infection is quite low. The rate of infection is less 
than 0.4 % of joint replacement surgeries. The causes for infection are generally 
contamination during the surgical procedure. These infections can be prevented mostly by 
good surgical practice [1, 2].  
Dislocation is the shifting of the replaced joint out of the replaced socket. Dislocations occur 
in 2 to 5% of patients undergoing total hip replacement. It is generally a consequence of high 
stresses on the joints generated by undesired postures or excessive physical activities [1, 2].  
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Figure 4 - Uncemented hip implants survival and reasons for hip arthroplasty revisions. 
(Adapted from the Swedish Total Hip Replacement Register
2
) 
 
1.2.1 Loosening  
Loosening is the major problem facing the long-term success of total joint replacements.  
The components of a joint arthroplasty may become loose over time. The patient denotes 
increased pain in his replaced joint. On the x-rays, areas of loosening are identified by 
radiolucent zones revealing the replacement of bone mineralized tissue by a soft fibrous tissue 
that does not provide the necessary mechanical support. Once a component becomes loose, it 
generally does not regain fixation in the future. For this reason, patients are followed on a 
regular basis with repeated radiographies to identify loosening risks. 
 
Theories of implant loosening and debate about debris particles and micromotions 
The exact processes that provoke the replacement of periprosthetic bone by a layer of soft 
fibrous tissue are still under debate. Two hypotheses are generally used to explain the etiology 
of periprosthetic bone resorption. The most supported theory focuses on a biological reaction 
                                                
2 jru.orthop.gu.se/ 
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to sub-micron size wear particles. Numerous studies have shown that the debris after implant 
wear induces inflammatory reactions in the tissues surrounding the implant [4-6]. The second 
hypothesis suggests that mechanical factors also contribute to osteolysis. In particular, 
micromotions at the bone-implant interface are suspected to play a key role in tissue 
differentiation [7]. 
 
1.2.1.1 Role of wear debris particles in aseptic loosening 
Wear at the articulating bearing surfaces can be defined as the removal of particles that 
occurs as a result of the relative motion between two opposing surfaces under load [8]. 
Total joint arthroplasty components are made of artificial materials. Over time, as these parts 
move back and forth relative to each other, this will result in wear of the components. Using 
radiostereometry, a very accurate measuring technique, Önsten et al. found a mean annual 
wear rate of hip components of 0.09 mm/year during a follow-up of 5 years [9].  
Once removed from the implant material, the wear debris remains within the tissue and fluid 
surrounding the total joint arthroplasty. In tissue retrieved from hip revisions of 15 patients, 
Korovessis and Repanti found granules or larger cement particles, polyethylene fibers and 
metal deposits [6].  
Previous studies have shown that these large amounts of wear particles of polyethylene, 
cement, metal, or ceramics set into motion a cascade of cellular events in the periprosthetic 
bone [4]. The particles activate macrophages, which in turn trigger osteoclasts activity via 
pro-inflammatory factors [10]. The resulting imbalance in local bone metabolism leads to a 
progressive and massive bone loss.  
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1.2.1.2 Role of mechanical factors in aseptic loosening 
Stress shielding 
Stress shielding has been reported for many implants designs. This is the consequence of the 
reduction of mechanical loading in the bone by the presence of an implant resulting in bone 
loss. Stress-shielding can be interpreted as the normal adaptation of bone to disuse [11]. 
 
Micromotions 
The presence of an interface between two materials of different mechanical properties in a 
mechanically loaded structure induces a slip at the interface. In a joint arthroplasty, the slip 
between the metallic component and the bone is generally referred to as micromotions 
because of its magnitude: in hip replacements for example, relative displacements up to about 
200?m were measured at the bone implant interface during normal gait cycles [12, 13].  
Micromotion of the implant components relative to the adjacent bone in patients undergoing 
total joint arthroplasty are thought to contribute to aseptic loosening. In a dog model, Jasty et 
al. found that micromotions lower than 40?m favor bone formation, while micromotions of 
higher magnitude lead to the creation of a fibrous tissue [14]. In a post-mortem study, Engh 
et al. found that cementless implants which showed signs of bony ingrowth had maximum 
relative micromotion of 40 μm, and implants which had failed bony ingrowth had relative 
micromotion of 150 μm [15]. Therefore it is believed that micromotions may facilitate 
osteolysis by enlarging the so-called effective joint space [16] and hence allow access of 
debris particles to wider areas of the bone-prosthetic interfaces.  
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1.2.2 Early resorption, an initiator of aseptic loosening? 
The origins of aseptic loosening are still unclear. However, although aseptic loosening is 
generally a long-term outcome, some studies suggest that it is initiated in the early post-
operative period.  
 
Early migration predicts loosening 
Rapid early migrations have been detected by roentgen stereophotogrammetry in many 
asymptotic hips, often as early as 4 months postoperatively [17, 18]. Similarly, in knee 
replacements, Petersen et al. measured migrations of the component of 0.7 mm already after 6 
weeks (Figure 5) [19]. These early migrations of the components have been found to predict 
an increased risk of clinical loosening [17, 20].  
 
Figure 5 - Clinical follow-up of total knee replacement migration. Most of the migration 
occurs within months post-operatively (adapted from [19]) 
 
Early migration is related to early periprosthetic bone loss 
Using a rabbit model, Dhert et al. demonstrated that immediately after implantation, a 
sequence of hematoma formation, bone resorption, and bone formation is initiated. As a result 
of this sequence bone–implant contact is temporary reduced (Figure 6) [21].  Moreover, in an 
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in vivo study of screw fixation in a rabbit model performed in collaboration with Stryker, we 
observed a small decrease of 10% of the screw pullout force at 5 days post-operatively; the 
decrease was compensated after 10 days and then the pullout force increased significantly at 
12 days (Figure 6) [22]. The reported decrease in bone-implant contact and pullout-force 
certainly reflects an early osteoclastic activity. 
 
Figure 6 - Early bone-implant contact loss and fixation loss in rabbit studies  
 (adapted from [21] and [22]).  
Furthermore, a clinical study showed that up to 14% periprosthetic bone is lost during the first 
three months after total hip arthroplasties [23]. And it was found that the early migration 
amplitude was correlated to the gravity of periprosthetic bone loss [19].  
Finally, it is interesting to note that Korovessis and Repanti, in their retrieved tissues study of 
non-loosened cases, had the opportunity to study the progressive development of the fibrous 
membrane and the first appearance of the cement debris. The first signs of the fibrous 
membrane appeared 2.5 months postoperatively, whereas the first cement debris were 
observed only seven months after the implantation of the prosthesis [6]. 
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To sum up, these results indicate that the fate of an orthopedic implant is mainly determined 
at an early stage, probably before any wear particles are produced and can reach the 
periprosthetic bone. Therefore this suggests that early bone loss is related to other factors, for 
example mechanical factors. Micromotions at the bone-implant interface are then ideal 
candidates to explain the initiation of periprosthetic resorption. But the exact chronology of 
the early stage events that finally lead to critical bone loss is unknown. In my first paper, the 
role of micromotions is further investigated. 
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1.3 Preview of paper 1: Microstimulation at the bone-implant 
interface upregulates osteoclast activation pathways.  
So far no data existed that quantified the effect of micromotions directly on human bone. We 
hypothesized that micromotions at the bone implant interface may activate bone resorption 
around the implant through bone cell signaling. We tested this hypothesis with an ex vivo 
loading system developed to stimulate human bone cores with micromotions. We observed 
significant up-regulation of the activation pathways of the bone resorbing cells. This 
suggested that the micromotions at the bone-implant interface have the potential to induce 
bone resorption after only one hour. (Full paper on page 44) 
 
1.4 Osteoclasts, a target to reduce periprosthetic bone loss? 
Based on the early resorption data and the results of the first paper [24], it seems clear that the 
efforts to treat aseptic loosening should be concentrated at the prevention of early 
periprosthetic bone loss. As this process seems to be initiated by micromotions which activate 
the osteoclasts almost immediately, it was proposed recently that blocking the osteoclastic 
resorption with bisphosphonate treatments might prevent the periprosthetic bone loss at short 
term, and thus limit the risk of aseptic loosening [25].  
This solution is discussed in chapter 3. Some elements of bone mechanobiology are 
introduced in chapter 2. These elements are necessary for the understanding of chapters 3.  
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2 Bone mechanobiology 
Bones purposes are the mechanical support of the body mass (load bearing support, 
momentum transfer), the protection of vital organs, the housing of hematopoeitic bone 
marrow and the stock of calcium and phosphate for the calcium homeostasis. To ensure these 
functions bones are modeled and renewed continually through the processes called bone 
modeling and bone remodeling. These processes ensure that bones shape and microstructure 
are adapted to the actual mechanical demand. Remodeling is also essential for maintenance of 
the calcium balance. Bone modeling and remodeling rely on the actions of the different bone 
cells that constantly ‘sense’ the mechanical demand, and adapt to this demand by resorbing 
old bone or synthesizing new bone.  
 
2.1 The skeleton 
The skeleton is the hard framework of the body. It is made of 206 bones of different shapes 
(long load-bearing bones, flat bone, mandible, vertebrae, etc.). Some bones have highly 
specialized functions, for example bones of the ear transmit sounds. Most long bones contain 
a dense outer shell made of cortical bone while the inside is made of trabecular bone, a fine 
network of connected bone trabeculae. The junction between the two types of bone is 
continuous. The relative proportion of cortical and trabecular bone varies in function of the 
anatomical location (Figure 7). The ends of the bones that form joints are covered with 
cartilage [26, 27].  
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Figure 7 - The skeleton is made of 206 bones of different shapes and sizes with various 
relative proportions of cortical and trabecular bone (source: cabinetmag
3
). 
 
2.2 Cortical and trabecular bone 
Cortical bone represents nearly 80% of the skeletal mass. It has a slow turnover rate and a 
high resistance to bending and torsion. It provides strength to resist bending at the middle of 
long bones. At microscopic level the cortical bone matrix is organized in lamellae of 3 to 
7 μm thickness, composed of collagenous fibers. The orientation of the fibers alternate, which 
gives compact bone its strength.  
                                                
3 Cabinet Magazine, a quarterly of art and culture, issue 28, www.cabinetmagazine.org/  
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Trabecular bone, also known as cancellous or spongy bone, represents only 20% of the 
skeletal mass but 80% of the bone surface. Trabecular bone is less dense, more elastic and has 
a higher bone turnover rate than cortical bone. Trabecular bone forms the interior scaffolding, 
which helps bone resist to compressive forces. Trabecular bone consists of a network of 
interconnected bone trabeculae with spaces filled with bone marrow. The trabeculae are of 
two types, rods and plates. Their size is less than about 0.2 mm (Figure 8) [26]. 
  
 
Figure 8 - Details of the microstructure of cortical bone and the junction  
with trabecular bone. (source: www.mednote.co.kr) 
 
2.3 Composition of bone 
The composition of bone varies with age, anatomical location and metabolism. Bone mineral 
accounts for 50% to 70% of adult bone, the organic matrix for about 20% to 40%, water for 
5% to 10 % and lipids for 1% to 5 %.  About 90% of bone organic matrix is composed of type 
I collagen.  Bone mineral is mostly composed of hydroxyapatite (HA), which provides 
rigidity and strength for mechanical functions of the skeleton (Figure 9) [28, 29].  
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Figure 9: The two main components of bone are hydroxyapatite and type I collagen.  
 
It is worth noting that its composition makes bone opaque, and thus optical microscopy 
techniques cannot be used to study bone structure or metabolism in situ. However, the high 
mineralization of the bone matrix allows the use of backscattered scanning electron 
microscopy (SEM) and x-ray microcomputed tomography (?CT) to image bone 
microstructure and density [30-34]. These are the core experimental observation techniques in 
papers 2 to 5.  
 
2.3.1 Bone quality 
The health of a bone is generally defined by its strength and stiffness. But these measures are 
not directly related to the risk of fracture. Bone mass density (BMD) is highly correlated with 
strength and stiffness but there is a less clear relation between BMD and the risk of fracture, 
because structural and geometric adaptation can compensate a decreased BMD. Another 
important parameter to define bone quality is its degree of fatigue. Cyclic loading, even at low 
strains, causes fatigue: a gradual reduction of strength and stiffness over time. In bone, the 
reduction in mechanical properties is attributed to the formation of microcracks [26, 35].  
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2.4 Bone renewal and adaptation 
In adults, ten per cent of the bone mass is replaced every year. This constant renewal, called 
bone remodeling, prevents the accumulation of microcracks and therefore allows bone to 
carry out its functions. Remodeling repairs bone defects that result from mechanical stresses, 
and maintains the optimal levels of calcium in the blood. Remodeling requires cells that 
resorb old bone, the osteoclasts, and cells that form new bone, the osteoblasts.  
The ability of bone to adapt to mechanical loads also relies on bone resorption and bone 
formation by bone cells. In the adaptation process, called bone modeling, resorption and 
formation occur at different locations and the bone morphology is changed. To adapt to 
mechanical demands, bone modeling requires cells that sense the mechanical stimuli, 
the osteocytes. 
 
2.4.1 Bone cells 
Four major types of cells participate actively in bone remodeling and modeling: osteoclasts, 
osteoblasts, osteocytes and bone lining cells.  
 
2.4.1.1 Osteoclasts 
Osteoclasts are the bone resorbing cells. These giants multinucleated cells containing 4 to 20 
nuclei, measure 20 to 100 μm diameter. They originate from hematopoietic stem cells into 
osteoclasts progenitors, then to pre-osteoclasts which fusion into mature osteoclasts. The 
maturation of osteoclasts is activated by osteoblasts’ cytokines [36, 37]. Mature osteoclasts 
attach to the bone tissue matrix and form a ruffled border at the bone/osteoclast interface that 
is completely surrounded by a “sealing” zone. This creates an isolated microenvironment in 
which the osteoclast secretes acids to dissolve the organic and inorganic matrices of the bone 
(Vaananen et al, 2000).  
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2.4.1.2 Osteoblasts 
Osteoblasts are the bone forming cells: they mineralize the bone matrix. These spherical, 
mononucleated cells, of 10 to 20 μm of diameter, originate from mesenchymal stem cells and 
differentiate into mature osteoblasts under the influence of local growth factors. Osteoblasts 
are highly enriched in alkaline phosphatase and secrete type I collagen and specialized bone 
matrix proteins as unmineralized osteoid at their bone-forming front. In a second time, the 
matrix is mineralized externally. During the process of bone matrix formation, some 
osteoblasts become embedded in their own matrix production and differentiate into 
osteocytes. The remaining osteoblasts synthesize bone until they eventually transform to 
lining cells that cover the newly formed bone surface [38, 39]. 
 
2.4.1.3 Osteocytes 
Osteocytes are the bone mechanosensory cells. There are numerous evidences that osteocytes 
are the mechanical sensors that signal to osteoblasts and osteoclasts where bone needs to be 
formed or resorbed [40, 41]. Osteocytes communicate with each other via cell processes 
extending through network of canaliculi [42-44].  
 
2.4.1.4 Lining cells 
Lining cells are thin elongated cells that cover the quiescent bone surfaces. Lining cells are 
highly interconnected with the osteocytes in the bone matrix via the canaliculi network (Lian 
& Stein, 2001). The bone lining cells are thought to be inactive osteoblasts, which can be 
activated to produce bone matrix for bone, modeling. Lining cells can retract prior to 
osteoclastic bone resorption [45, 46].  
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2.4.2 Bone remodeling and bone modeling 
Bone modeling and remodeling are not very different at the cell level, as they fundamentally 
rely on bone resorption and bone formation, but their final effect on the bony structure is very 
different.  
 
2.4.2.1 Bone remodeling 
Bone remodeling begins at a quiescent bone surface with the retraction of lining cells and the 
appearance of osteoclasts. There, osteoclasts acidify and dissolve the bone matrix. In a second 
time, osteoblasts appear at the same site, deposit osteoids and mineralize them, to form new 
bone. In bone remodeling, osteoclasts and osteoblasts closely collaborate in a Basic 
Multicellular Unit (BMU). The tip of a BMU is made of osteoclasts, which resorb bone, 
followed by several thousands of osteoblasts that fill the tunnel (in cortical bone) or the canal 
(on trabeculae surfaces) (Figure 10a). BMU gradually burrows through the bone with a speed 
of 20-40 ?m/day [47, 48]. 
 
2.4.2.2 Bone modeling 
In bone modeling, formation and resorption of bone are not balanced and bone formation is 
not necessarily preceded by resorption (Figure 10b). Lining cells at the bone surface can 
differentiate back to osteoblasts and form new bone on top of old bone, while osteoclasts can 
resorb bone where lining cells have retired without forming a BMU. Modeling can result in 
changes of the bone micro-architecture, the bone mass and the shape of the bones [49, 50].  
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Figure 10 - (a) in bone remodeling osteoclasts precede osteoblasts. (b) In bone modeling 
resorption and formation can occur at different locations (source: Surgeon General 
4
). 
 
2.4.2.3 Biological regulation of bone adaptation 
Local regulation 
Osteoblasts produce several cytokines that regulate the osteoclasts formation and activity. In a 
BMU for example, the coordination between bone resorption and formation relies on this 
local regulation. Osteoblasts produce the macrophage colony-stimulating factor (m-CSF). M-
CSF, which binds to its receptor on preosteoclastic cells, is necessary for osteoclast 
development [51]. But the most interesting regulatory system is RANKL/OPG [52]: 
osteoblasts produce the receptor activator of nuclear kappa B ligand (RANKL) that resides 
on their outer cell membrane [53, 54]. RANKL can bind to its receptor (RANK) on 
osteoclasts precursors and stimulate their differentiation. So, when an osteoclast precursor 
encounters an osteoblast, the resulting interaction between RANK and RANKL stimulates the 
osteoclast precursor to mature into a fully differentiated, bone-resorbing cell [53, 54]. But 
osteoblastic cells also secrete osteoprotegerin (OPG), the soluble decoy receptor of RANKL, 
which can bind to RANK and disable it and therefore inhibiting osteoclastic differentiation 
                                                
4 www.surgeongeneral.gov 
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and activation by RANKL (Figure 11) [55]. So, the balance between RANKL and OPG 
regulates the number and activity of osteoclasts and thus the rate at which bone is resorbed 
[56, 57].  
 
 
Figure 11 - Local regulation of osteoclasts differentiation and  
activation by RANKL/OPG. (source: Surgeon General 
5
). 
 
Hormonal regulation 
Bone cells have receptors for sex steroids and other hormones [58]. Estrogen, parathyroid 
hormone (PTH) or factors such as 1,25 dihydroxy D (vitaminD) can alter the osteoblasts 
RANKL/OPG production ratio and therefore modulate the action of bone cells [59]. For 
example, hormonal control allows calcium to be released from bone when it is needed 
elsewhere in the metabolism by increasing the bone resorption rate [59, 60]. 
 
                                                
5 www.surgeongeneral.gov 
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2.4.2.4 Regulation of bone adaptation by mechanical factors 
It is obvious that mechanical factors have a major influence on bone adaptation, since their 
effects on bone morphology have been observed for more than a century. Adaptations of bone 
to specific mechanical situations have been reported in numerous studies. In intense physical 
activities, bone adapts to the specific loading. For example, the lumbar spine of professional 
weight lifters have 13% higher bone mineral content (BMC) than controls [61]. The loaded 
humerus and radius of professional female racquet-sports players are up to 28% stronger than 
the unloaded ones [62]. Lower limbs of soccer players exhibit 10% higher BMC than age-
matched controls [63]. On the other hand, when the mechanical demand is reduced, bone 
adapts by decreasing its mass and mechanical properties to the required levels. For example, 
when elite athletes reduce their training as their careers end, they generally loose their “extra” 
bone rapidly [63]. In the same manner, during long periods of disuse, such as in space flights, 
bone loss can be as fast as 7% of BMC after 4 weeks flights [64].  
 
The current understanding of the mechanical regulation of bone adaptation is that bone is 
regulated locally. This idea originates from Roux (1881), who proposed that bone adaptation 
is self-organized. More recently, Frost captured these assumptions in his ‘mechanostat’ theory 
[65-68]. In this theory, local strains regulate bone mass: if strain levels exceed a formation 
threshold, bone is formed, but in contrary, when strain levels are below a resorption threshold, 
bone is removed (Figure 12). This qualitative approach is the basis for numerous 
mathematical and computational models that were developed to study bone adaptation to 
specific mechanical situations [11, 69-73]. 
 30
 
Figure 12 - Graphical interpretation of Frost's mechanostat (adapted from [68]). Typical 
strain magnitude in human bone range from 0 to about 2000?? [74]. 
 
2.4.2.5 Mechanosensation and mechanotransduction 
Frost’s mechanostat is a qualitative theory and it does not concern the underlying cellular 
mechanisms. Bone adaptation necessarily involves the perception of mechanical loading 
signal or mechanosensation and the translation of this signal into an action or 
mechanotransduction.  
The precise biological pathways by which mechanical loads stimulate bone formation and 
suppress resorption, whereas unloading has the opposite effect, is still an unresolved issue in 
bone mechanobiology. The most accepted hypothesis states that osteocytes have a primary 
function in the transduction of mechanical signals. Several studies revealed that these cells 
respond to mechanical stimulation such as strains or fluid flow by the mean of their surface 
receptors, but it is not clear if the dendritic processes, the cell body or cilias are the 
mechanosensors [75-77]. Moreover, osteocytes are mutually connected by a network of 
canalicular channels (Figure 13). It is hypothesized that the intra-canalicular fluid-flow driven 
by mechanical loadings imposes a shear stress on osteocytes, and therefore acts as strain 
amplificator [78].  
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Cells in this network apparently communicate together through dendritic processes and gap 
junctions [79]. At the bone surface, this network also connects with the lining cells. Thus, 
osteocytes and lining cells form a functional syncytium, which is ideally located and is well 
suited for signal transduction [80, 81]. Mechanically stimulated osteocytes may then transfer 
signals through the canaliculi network to the bone surface to control osteoclast and osteoblast 
activity [42]. But this theory has not yet been formally proven.  
 
There is still a debate about the fundamental nature of the signal that is perceived by the 
osteocytes. Beside the fluid-flow theory, others define this signal as the result of microcracks 
on the osteocytes network and the consequential osteocytes death [44, 82], while other studies 
identified this signal as purely mechanical properties, such as the surface strain energy [11, 
73].  
 
Figure 13 - (a) An osteocyte with its dentritic process entering the canaliculi network.  
(b) Osteocytes form a network, which is ideally featured for signal transduction
 6
  
                                                
6 source: (a) www.visualhistology.com, (b) www.cornell.edu/BioG 
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3 Prevention of periprosthetic bone loss 
with local delivery of bisphosphonate 
As suggested in section 1.2.2, the fate of orthopedic implants seems to be principally 
determined at an early stage. The lack of initial fixation promotes a positive feedback with 
bone-implant micromotions appearance, debris particulate formation and osteoclastic 
resorption that can finally lead to critical bone loss [20, 83, 84]. In contrary, when primary 
stability is achieved, the long-term survival of the implant is significantly improved [17, 18].  
Based on these observations, Horowitz and Gonzales proposed to improve the implant 
fixation by preventing the early post-operative resorption through the action of drugs that 
inhibit osteoclastic activity, namely, bisphosphonates [25]. 
 
3.1 Bisphosphonates 
Bisphosphonates are synthetic molecules characterized by a P–C–P group. They have been 
used in industry since the late 19th century. Bisphosphonates inhibit the precipitation of 
calcium phosphate and also slow down the dissolution of these crystals. In 1968, Fleisch et al 
demonstrated that bisphosphonates have a potentially interesting biological effect: in vivo, 
bisphosphonates inhibit bone resorption [85]. Hence, bisphosphonate were rapidly used in 
medicine to prevent bone resorption in diseases like osteoporosis and Paget’s disease7 [86]. 
                                                
7 Osteoporosis is the low bone mass disease. It is characterized by the progressive thinning of bone 
tissue and loss of bone density over time. Paget's disease is a metabolic bone disease that involves 
bone destruction and regrowth, which results in deformities and pain. 
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Eight bisphosphonates are commercially available today and more are in development (Figure 
14).  
 
Figure 14 - Chemical structure of four famous bisphosphonates available on the market. 
From left to right: alendronate, pamidronate, ibandronate and zoledronate [91].  
 
The commercially available bisphosphonates are administered orally or injected. All 
bisphosphonates have low and variable bioavailability independently of the administration 
route [87]. With high water solubility and high ionization, they penetrate biological 
membranes of the gastrointestinal tract poorly and thus the bioavailability is as low as 2% of 
the oral dose and can be lower if absorbed together with food [88]. The determination of the 
drug level in the bone metabolism in vivo is inaccurate [87].  
Systemic administration of bisphosphonate presents several adverse effects like fever, ulcers 
and, in patients with metastases, osteonecrosis of the jaw [89, 90].  
 
3.1.1 Bisphosphonates’ mechanisms of action 
Bisphosphonates have a high affinity for hydroxyapatite, and therefore localize onto bone 
mineral surfaces.  In particular, bisphosphonates appear to localize to sites of osteoclast 
activity rather than at sites of bone formation [92]. Bisphosphonates are released from the 
bone matrix during its resorption and are internalized by osteoclasts. There, the molecules 
inhibit key metabolic enzymes, and interfere with a variety of cellular functions essential for 
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the activity and survival of osteoclasts [93, 94], sometimes ending by the programmed cell 
death, or apoptosis [95]. 
Yet, recent studies have demonstrated that some bisphosphonates such as alendronate, 
risendronate and zoledronate, beside their role as inhibitors of osteoclastic activity, are also 
promoters of osteoblast proliferation and maturation [96, 97]. 
 
3.1.2 Skeletal effects of bisphosphonates 
Numerous clinical studies have analyzed the skeletal effects of bisphosphonate in 
postmenopausal women8. Bisphosphonates therapies generally suppressed biochemical 
indices of bone resorption to about 50% of baseline after one month, while bone mineral 
density (BMD) increased slowly (2–6%) during the first year of treatment [98, 99]. From a 
traumatology point of view, the most striking effect of bisphosphonate therapies is the durable 
reduction of vertebral and hip fractures in patients with osteoporosis, therefore increasing 
considerably the comfort of these persons [100, 101], as fractures are the primary cause of 
morbidity in patients with osteoporosis [102, 103]. 
 
3.2 Effects of bisphosphonates on periprosthetic bone  
Recent studies have shown that bisphosphonates can preserve periprosthetic bone stock in 
animal studies and clinical trials. These therapeutic approaches of periprosthetic bone 
resorption can be classified in three categories with respect to the delivery route: systemic, 
topical and local. In general, these approaches have all been shown to reduce periprosthetic 
resorption.  
                                                
8 After menopause women face a significant risk of having osteoporosis 
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3.2.1 Systemic bisphosphonate treatments 
Previous studies have demonstrated that systemic administration of bisphosphonates enhances 
the quality of the bone-implant interface. In dogs, alendronate increased bone ongrowth, bone 
density and shear strength of the bone implant interface by 24%, 60% and 10% respectively 
[104]. In rats, ibandronate reduced the implant osseointegration delay by 52% [105]. Finally, 
recent clinical data showed that post-operative treatment with systemic administration of 
clodronate prevents knee prosthesis migration at short term and at 4-years follow up [106, 
107].   
Systemic bisphosphonate seems then to be an easy and efficient way to prevent periprosthetic 
bone loss and therefore enhance the long-term outcome of orthopedic implants. However, 
systemic bisphosphonate treatments induce risks of secondary effects such as described 
previously. It is probably not acceptable to expose patients to these morbid adverse effects 
when they do not have osteoporosis. Furthermore, given the very low bioavailability of 
bisphosphonates, the drug has reduced probabilities to reach the implant locations on time to 
prevent early resorption, and the dose that finally reaches this location is unpredictable.  
 
3.2.2 Topical bisphosphonate applications 
Because of the drawbacks associated with the systemic use of bisphosphonates, local 
treatments seem to be more suitable for the prevention of periprosthetic bone loss. Topical 
applications of bisphosphonate consist of rinsing the implant, the implant’s cavity, or both, 
with a solution of bisphosphonate just before the implant is inserted. The efficiency of this 
technique was demonstrated in a few recent studies: in dogs, topical alendronate increased 
periprosthetic bone density by 85% and bone-to-implant contact by 89% [108, 109]. In a 
remarkable clinical study, topical application of clodronate decreased knee prosthesis 
migration by 28% [106]. 
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There are several drawbacks associated with topical applications. First, this method adds an 
extra step in the surgical procedure; this induces additional costs and increases surgical risks, 
such as infections or technical errors. More importantly, the technique does not guarantee a 
precise distribution of the drug. It is likely that some of the rinsing solution ends up in 
undesired sites, such as the periost, the muscles or the cardiovascular system with 
unpredictable effects. Finally, it has to be noted that most of the drug in the rinsing solution is 
wasted during the rinsing process.  
 
3.2.3 Local bisphosphonate release 
The drawbacks associated with systemic and topical treatments can be avoided with the third 
technique: local bisphosphonate release or drug delivery. It consists of grafting the drug onto 
the implant surface, by the mean of a carrier material, for example a thin layer of 
hydroxyapatite. Once the implant is inserted, the drug is released from the carrier directly at 
the desired site, which in the present case is the periprosthetic bone. By varying the carrier 
material properties, it is then possible to release the drug at different rates, in function of the 
needs. Furthermore, if the drug release is controlled, the optimal dose is delivered and 
immediately active.  
Local delivery avoids extra surgical procedures, as the bisphosphonate coating can be 
prepared in advance. This technique also ensures that the drug is restrained in the 
periprosthetic area and that the amount of drug is controlled and limited.  
Recent studies assessed local bisphosphonate delivery from an implant: Roussiere et al. have 
shown that the loading and release of zoledronate on and from hydroxyapatite are controllable 
and that the released molecule is intact [110]. In vivo, in rats, cortical screws releasing 
ibandronate and pamidronate from multi-layers of fibrinogens increased the pullout force by 
two-folds at 8 weeks [111]. Furthermore, in rats and osteoporotic rats, implants releasing 
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zoledronate increased the pullout force by 30% and the peri-implant bone density by 50% 
[112].  
In regard of these results, local delivery is a very promising technique. However, one limiting 
aspect of the technique is that, according to Peter et al., the intensity of the effect is clearly 
non-proportional to the released bisphosphonate dose [112, 113]. Small doses of 
bisphosphonate have a beneficial impact on periprosthetic bone stock and implant fixation, 
while excessive doses suppress this beneficial effect (Figure 15a). Moreover, some 
bisphosphonates, such as zoledronate, have been shown to increase in vitro the proliferation 
of osteoblasts at reasonable concentrations, but also to reduce their activity and proliferation 
at excessively high concentrations (Figure 15b) [114].  
 
Figure 15 - (a) The non-linear relationship between zoledronate dose and periprosthetic bone 
density, and implant pullout force (adapted from [112]). (b) In vitro, high concentrations of 
zoledronate reduce osteoblasts proliferation (adapted from [114]). 
 
For these reasons, drug-delivering implants are difficult to design: when developing an 
implant, it is essential to predict where the drug will diffuse and to produce designs that 
prevent the released bisphosphonate from accumulating excessively in periprosthetic bone. A 
biophysical model of the bone adaptation arising around drug-releasing implants would 
 38
certainly provide a powerful tool to further develop the technology. In paper 2, a theoretical 
model of periprosthetic bone adaptation with zoledronate delivery is developed and validated 
in vivo.  
 
Finally, to validate the local release of bisphosphonate for a medical use, more data is needed. 
To date, studies were conducted only with rats, in which bone biology is slightly different 
from bone biology of humans. Therefore, efficiency evidences of the local delivery technique 
must be obtained in big animals prior to planning clinical studies. In paper 3, we show that 
local zoledronate delivery from an implant increases periprosthetic bone density in sheep. 
 
3.3 Preview of paper 2: Development and validation of a 
theoretical framework to predict the bone density around 
orthopedic implants delivering bisphosphonate locally 
The aims of the second paper were, first, to develop a model of bone adaptation around an 
implant delivering zoledronate based on our previously published results [112], second, to 
predict the dose that would induce the maximal periprosthetic bone density, and third to 
verify in vivo that periprosthetic bone density was maximal with the calculated dose. 
In the mathematical model, the change in bone density is driven by a mechanical stimulus and 
a drug stimulus. The mechanical stimulus function was obtained from previous work [72, 73] 
and the drug stimulus function was identified numerically from experimental data. Implants 
with the calculated optimal dose of zoledronate were set in rats femurs and we measured that 
periprosthetic bone density was 4% greater with this dose compared to the dose previously 
described as the best one. (Full paper on page 64) 
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3.4 Preview of paper 3: Implants delivering bisphosphonate 
locally increase periprosthetic bone density in an osteoporotic 
sheep model 
The aim of the fourth paper was to verify the positive effect of local bisphosphonate delivery 
on the periprosthetic bone density of osteoporotic sheep. Implants coated with zoledronate 
and control implants were inserted in the femoral condyle of ovariectomized sheep for 4 
weeks (Figure 16).  The bone at the implant surface was 50% higher in the zoledronate-group 
compared to control group. The results of this trial study support the claim that local 
zoledronate could increase the fixation of an implant in weak bone. (Full paper on page 85) 
 
 
Figure 16 - In the study presented in paper 3, implants were implanted in sheep condyles.  
(a) ?CT view of an implant in the condyle. (b) SEM view of the periprosthetic bone structure.  
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3.5 Interactions between bisphosphonate and mechanical 
stimulations on bone adaptation 
In the reference studies [112, 113] and the studies described in papers 2 and 3, the implants 
were not specifically loaded mechanically. In the clinical situation of load-bearing implants 
such as total joint replacements, the periprosthetic bone is exposed to intense mechanical 
stimulations [11], and in this case, the modulation of the bone response by bisphosphonate 
remains uncertain. 
As described in section 2.4, bone adaptation is a process that relies on the communication 
between bone cells. Given that bisphosphonates reduce the activity of osteoclasts and may 
enhance the proliferation of osteoblasts, the communication between bone cells in response to 
mechanical stimulations might be altered. Moreover, bisphosphonate reduce the bone 
turnover rate, thus the bone matrix is less frequently renewed. The bone matrix gets more 
mineralized and therefore can get stiffer. In these conditions, the fluid flows that osteocytes 
sense when bone is exposed to mechanical loading might be accelerated because of the stiffer 
canalicular walls. This can induce higher shear stresses on the osteocytes receptors and thus 
artificially increase the mechanosensation. 
Very few studies have been performed on the subject. In osteoporotic rats a possible positive 
synergistic effect between alendronate and exercise has been detected but not confirmed 
[115], while in humans the effect of strength training combined with bisphosphonate  was not 
significantly different than training only [116, 117]. Nevertheless, in these studies, the strains 
induced by exercise training were much lower than strains that may exist proximally to a load 
bearing orthopedic implant. Therefore the question of bone response modulation by 
bisphosphonate in high strains conditions remains open.  
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The last two papers of the thesis concern an in vivo study of the effect of bisphosphonates 
plus intense strains on bone adaptation. First, theoretical aspects of the loading method are 
described in paper 4 and then the preliminary in vivo results are reported in paper 5. 
 
3.6 Preview of paper 4: 3D strain map of axially loaded mouse 
tibia: a numerical analysis validated by experimental 
measurements 
The aim of paper 4 was to calculate the 3D strains map of an axially loaded mouse tibia. A 
combined experimental/numerical study was performed to calculate the octahedral shear 
strain map. This study was motivated by the fact that, in this in vivo mouse model, the 
analysis of bone adaptation should be performed at the zone of highest mechanical stimulus to 
maximize the measured adaptations. It is concluded that quantification of bone remodeling 
should be performed at the tibial crest and at the distal diaphysis. The numerical model could 
also be used to furnish a more subtle analysis of the correlations between local strain and 
bone adaptation. (Full paper on page 106) 
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3.7 Preview of paper 5: Combined effects of zoledronate and 
mechanical stimulation on bone remodeling in an axially 
loaded mouse tibia.  
The aim of the fifth paper was to assess the interactions between zoledronate and mechanical 
loading on bone adaptation in order to anticipate bone evolutions when using bisphosphonate 
in highly loaded bone structures such as periprosthetic bone. We combined an in vivo axial 
compression model of the mouse tibia and injections of zoledronate. Bone adaptation was 
assessed with in vivo ?CT and 3point-bending. Axial loading induced a localized increase of 
cortical thickness and bone area. Zoledronate increased cortical thickness, bone perimeter, 
and bone area. In highly loaded sites, the effect combined zoledronate and mechanical 
stimulation was significantly smaller than the sum of the effects, which suggested that an 
interaction might exist at high levels of strains. (Full paper on page 123) 
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Abstract 
Peri-implant bone resorption after total joint arthroplasty is a key parameter in aseptic loosening. 
Implant wear debris and biomechanical aspects have both been demonstrated to be part of the 
bone resorption process. However, neither of these two parameters has been clearly identified as 
the primary initiator of peri-implant bone resorption. For the biomechanical parameters, 
micromotions up to 163μm were measured at the bone implant interface during normal gait 
cycles. The amplitude of the micromotions was shown to trigger differentiation of bone tissues. 
So far no data exists directly quantifying the effect of micromotions and compression on human 
bone. We hypothesize that micromotions and compression at the bone implant interface may 
induce direct activation of bone resorption around the implant through osteoblasts-osteoclasts 
cell signaling in human bone. This hypothesis was tested with an ex vivo loading system 
developed to stimulate trabecular bone cores and mimic the micromotions arising at the bone-
implant interface. Gene expression of RANKL, OPG, TGFB2, IFNG and CSF-1 were analyzed 
after no mechanical stimulations (control), exposure to static compression or exposure to 
micromotions. We observed a 8-fold up-regulation of RANKL after exposure to micromotions, 
and down regulation of OPG, IFNG and TGFB2. The RANK:OPG ratio was up regulated 24 
fold after micromotions. This suggests that the micromotions arising at the bone-implant 
interface during normal gait cycles induce a bone resorption response after only one hour, which 
occurs before any wear debris particles enter the system.  
 
Keywords 
Bone resorption; Orthopedic implant; Mechanical stimulation; Gene expression; Micromotions 
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Introduction 
After total joint arthroplasty, a radiolucent zone is frequently observed at the interface of bone 
and implant [4, 29]. This radiolucent zone is associated with a progressive peri-implant bone 
resorption. The implant fixation is affected, therefore inducing a risk of aseptic loosening. This 
becomes a serious problem as aseptic loosening accounts for more than two-third of hip 
revisions in Sweden, country where an extensive implant register has been set up since many 
years [16].  
Two hypotheses are generally used to explain peri-implant bone resorption. The first hypothesis 
focuses on a biological reaction to wear particles. Numerous studies have shown that the debris 
after implant wear induces inflammatory reactions in the tissues surrounding the implant [2, 7]. 
Bone formation may also be impaired by the presence of particles, such as titanium debris which 
were shown to induce apoptosis to osteoblasts culture in vitro [24]. In all cases, particulate 
debris accumulates in the tissue surrounding the implant. Upon accumulation, a chain of cellular 
events is triggered within the tissue leading to periprosthetic osteolysis and implant loosening 
[15]. The second hypothesis used to explain peri-implant bone resorption is based on 
biomechanical considerations. A stiff metallic implant in a load bearing bone considerably 
changes the mechanical state of the bone. Based on a numerical approach, Huiskes and 
Nunamaker showed that bone resorption around the implant is associated with high peak 
stresses immediately post-operatively [8]. The bone structure is affected by the new stress 
patterns around an implant. Numerical models also predict bone loss around the implant based 
only on these modified mechanical patterns [33].  
Mechanical effects play certainly also a crucial role at the bone-implant interface. The pumping 
action of the implant during gait cycle causes load fluctuation within the hip joint fluid. Using a 
numerical model, the interfacial compressive stress involved was found to be between 2x10-3 and 
0.1MPa [27]. Beside compressive stress, micromotions at the interface have been suspected to 
play a key role in tissue differentiation around the implant. It has been calculated that 
micromotions between 5 and 100μm occur at the bone–hip implant interface during normal gait 
cycles [27]. Mandell et al. analyzed the case of conical-collared intramedullary hip stem and 
reported micromotions up to 163μm in the worst design [17]. From an experimental point of 
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view, Baleani et al. quantified bone-implant micromotions under torsional load with position 
transducers in a hip implant model. A maximum of 56μm was measured in uncemented stems 
[1]. Finally, with in vivo models, Jasty et al. found that micromotions lower than 40μm favor 
bone formation in dog, while micromotions higher than 100μm lead to the creation of a fibrous 
tissue [10].  
Based on clinical observations, numerical and experimental biomechanical analysis and in vivo 
experiments, there is strong evidence to support the theory that micromotions and compressive 
stress at the bone-implant interface play an important role in the process of peri-implant bone 
resorption. However, thus far no data exists quantifying directly the effect of micromotions and 
compression on human bone. Therefore we hypothesize that micromotions and pressure at the 
bone implant interface may induce direct activation of bone resorption around the implant 
through osteoblasts-osteoclasts cells signaling in human bone. This hypothesis is tested with an 
ex vivo loading system using human bone samples. 
 
Materials and methods 
Bone samples preparation 
Twenty-five human femoral heads were obtained from the Hôpital Orthopédique de la Suisse 
Romande following total hip prosthesis procedures (Ethical Protocol 51/01, University of 
Lausanne). In the next 4 hours following the sample collection, each femoral head was fixed 
axially in a custom fixation device and at the central section a 6 mm thick slice was extracted 
with a surgical saw. Then, 4 to 16 trabecular bone cores of radius 3 mm and height 6 mm were 
extracted from the slice with a biopsy puncher (Shoney Scientific, Pondicherry, India) at 15mm 
from the cortical bone layer (see Figure 1 A-D). The bone cores were then incubated overnight 
in DMEM (Sigma, Buchs, Switzerland) containing 10% of fetal bovine serum (Sigma), and 1% 
of PSF (100X, 10’000 U/ml Penicillin, 10’000μg/ml Strepzin, 25μg/ml Fungizone) 
(GibcoBRL, New York, USA) at 37°C, 5%CO2, 90%H2O.  
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Initial Gene Expression Level 
Nine samples were used to control the initial gene expression level after sample preparation. 
Three samples were collected immediately after punching, three samples 24hours after punching 
and three samples 48h after punching. These nine samples were not mechanically stimulated but 
placed in 1ml Trizol (Invitrogen AG, Switzerland) and stored at -80°C for later RNA extraction.  
 
Bone samples stimulation 
A device was developed to apply combined compression and micromotions regimen on the 
surface of trabecular bone samples simulating then the mechanical situation arising at the bone-
implant interface [23]. Briefly, the device consists of a bottom fixed and top moving plates with 
bone core placed in between (Figure 1 F). A 0.5MPa static compression was applied from top 
and sinusoidal micromotions of 100μm at a frequency of 1Hz were applied on the top bone 
surface.  
 
A Finite Element Analysis was performed to evaluate the mechanical stimulation in the bone core 
corresponding to the experimental boundary conditions. Because of the relative low frequency 
and high porosity, the inertial and fluid effects were omitted in this numerical study. The bone 
sample was assumed elastic, homogeneous and isotropic, and the contact was assumed to follow 
a Coulomb friction law. The elastic modulus was 250MPa [19] and the bone-metal friction 
coefficient was 0.2 [14, 28]. For the compression case, the volume average of the octahedral 
normal and shear strains were respectively 286 and 1190 microstrains. When micromotions 
were added to compression, normal stains were not affected, but shear strains increased by 7% 
(Figure 2). 
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Figure 1 - Bone core extraction procedure: each femoral head was fixed axially with two 
screws in a custom fixation device (A). Using a surgical saw a 6mm thick slice was extracted 
from the central section of the femoral head (B). Each bone core was extracted manually from 
the slice with a biopsy puncher (C). The bone core was extracted manually from the biopsy 
puncher and rinsed (D). Histogram distribution of patient age from whom femoral head has 
been collected to process the cylindrical bone cores. No significant correlation was observed 
between age or sex and genetic expression following mechanical stimulation (E). The bone core 
was inserted in the microstimulation device, which was placed in a dedicated incubator during 
the mechanical stimulations. The upper part applies a 0.5MPa static compression and 100μm 
micromotions on the top of the bone core. The device is controlled with a computer (F). 
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The bone cores were separated randomly into three groups: control, compression and 
micromotions. Bone cores from the control group were incubated for one hour at rest in 1 ml 
culture medium (control). Bone cores from the compression group were incubated in 1 ml 
culture medium and a static compression of 0.5MPa was applied vertically on the sample in a 
special chirurgical steel chamber during 1 hour (compression).  Bone cores from the 
micromotions group were incubated in 1ml culture medium. A 0.5MPa static compression was 
applied from top and sinusoidal micromotions of 100μm at a frequency of 1Hz were applied on 
the top surface during 1 h (micromotions). The parameters of the sample stimulations were 
chosen according to the results of previous numerical studies performed in our laboratory [27] 
and corresponded to a normal load during gait cycles.  
 
 
Figure 2 - A finite element analysis provided an estimation of the octahedral normal and shear 
strains, for the compression and micromotions cases. When micromotions were added to 
compression, normal strains did not changed, but shear strains increased by 7%. For 
illustration purpose, the deformation of the finite element mesh is magnified by 20. 
 
RNA extraction  
Immediately after the stimulations, each sample was placed in individual tube containing 1ml 
Trizol and stored at -80°C. The bone samples were mixed with a stainless steel bead (QIAGEN 
Gmbh, Germany) deposited in each tube by shaking the tubes three times in the MM300 Mixer 
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Mill (Retsch GmbH & Co, Hann, Germany) at 30Hz during 30s. Then, 0.2ml of chloroform 
(Sigma-Aldrich, Switzerland) was added to the homogenate. The tubes were shaked manually, 
and after phase separation, 0.5ml of the upper phase was transferred in new tubes where 0.5ml 
of ice-cold isopropanol (Sigma-Aldrich) was added. Tubes were vortexed, and stored overnight 
at -80°C. RNA was isolated and purified with NucleoSpin columns (Macherey-Nagel, Düren, 
Germany) according to the protocol furnished by the manufacturer. The concentration and 
quality of the extracted RNA was measured with a biophotometer (Eppendorf AG, Germany), 
RNA integrity was verified by optical density (OD) absorption ratio A260/280 nm. OD between 
1.7 and 2.2 was chosen as a criterion on quality for inclusion (adapted from Cambridge Systems 
Biology Centre, Cambridge, UK). RNA was eluted in 40μl of RNase-free water and stored at -
80°C until further processing. 
 
First strand synthesis 
The isolated RNA was reverse-transcripted to cDNA with the StratScript enzyme (Stratagene, 
San Diego, CA). For each sample, 5μl of total RNA was reverse-transcribed using the Taqman 
Universal polymerase chain reaction (PCR) reagents with random hexamers (Applied 
Biosystems, Foster City, CA). Reaction volumes were fixed at 50μl according to the protocol 
provided by the supplier. The thermal cycler PCT-0100 (MJ Research, Waltham, MA) was 
programmed as following: 25°C 10 min, 48°C 30 min, and 95°C 5 min. 
 
qPCR 
The following gene expressions were quantified: RANK ligand (RANKL), Osteoprotegerin 
(OPG), Interferon-gamma (IFNG), Colony Stimulating Factor 1 (CSF-1) and Transforming 
Growth Factor beta2 (TGFB2) as target genes, and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as non-regulated reference gene (housekeeping gene). 
Specific primers for each gene were designed with the Primer Express® software (Applied 
Biosystems) and purchased from Integrated DNA Technologies (Coralville, IA). An additional 
sequence of 18bp was added to the 5’ end of every forward primer to use the Amplifluor 
Universal Detection System (Intergen Discovery Products, Purchase, NY). PCR reactions were 
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performed in 25μl: 5μl of first strand, 12.5μl of TaqMan Universal PCR Master Mix (Applied 
Biosystems), and 7.5μl of the primers working solution. Thermal cycle conditions were 50°C 2 
min, 95°C 10 min, then 50 cycles at 95°C 15s, 60°C 1 min. Amplifications were monitored with 
the ABI Prism 7700 (Applied Biosystems). Measurements were performed in duplicates.  
 
Gene expression analysis and statistics 
The threshold cycle CT was measured for each gene and each sample from the PCR 
amplification curve with a standard routine. CT table was analyzed for each gene in each 
experiment: if duplicates from one cDNA presented a difference larger than 3 cycles (due to 
experimental artifacts such as limited pipetting precision, presence of bubble in the well, etc.), the 
measure was dismissed; otherwise CT was calculated as the duplicate mean. If CT was greater 
than 35 cycles, the measure was dismissed.  
Relative gene expressions were calculated with the 2-??CT method [22] with GAPDH as 
housekeeping gene. As the level of GAPDH expression may be influenced by the mechanical 
stimulation and consequently would render invalid its use as reference gene, in a pilot study we 
normalized the GAPDH expression by the level of 18S expression. No effect of mechanical 
stimulation was observed on GAPDH expression (data not shown). Unless 18S is similarly 
regulated as GAPDH through mechanical stimulation, which seems to be unlikely, GAPDH 
gene expression can be used as a stable reference gene in this experiment. We used a 
randomization of the differences and one-way ANOVA to compare the gene expressions of the 
different groups [6]. All values were then normalized to the expression of the control group. All 
mathematical operations and statistical analysis were performed using Mathematica® (Wolfram 
Research, Inc. USA).  A p-value lower than 0.05 was considered significant while p-value lower 
than 0.1 was considered as a strong trend. 
 
 53
Results  
In the following results, we report normalized gene expressions as MEAN±SEM. 
 
Sample collection 
The bone core samples were obtained from femoral heads of male and female patient between 50 
and 80 years old (Figure 1 E). No significant correlation was observed between age or sex and 
genetic expression following the experiments. Table 1 summarizes the number of cylindrical 
cores in each group. One hundred and twelve samples were used in the main experiment. Fifty-
four samples passed the quality criteria (A260/A280) and were used for normalized gene 
expression analysis comparison between control, static compression and micromotions regimen. 
 
# of bone cores Control Compression Micromotion 
112 62 20 30 
 
Table 1 - Number of bone cores used for each condition 
 
Initial gene expression level 
As the process of bone core extraction may affect the gene expression of the sample, nine 
samples were used to evaluate the initial and 24h gene expressions level after samples 
preparation and compare it to the value obtained 48h after sample preparation. Immediately after 
sample punching, gene expressions were the following: RANKL 0.68±0.25, OPG 1.5±0.7, 
TGFß 3.2±0.7 compared to the 48h values. After 24h, the expressions were: RANKL 0.5±0.2, 
OPG 0.6±0.2, TGFß 0.9±0.2 compared to the 48h values. Finally, after 48h, when we compare 
the values between each sample, the expressions became: RANKL 1.4±0.5, OPG 0.77±0.12, 
TGFß 1.0±0.2 (Figure 3).  None of the expressions at 48h were significantly different from 
one, meaning that the gene expression of all core samples was similar . None of the expression 
levels at 24h were significantly different from those at 48h. The variances of the expression 
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levels were significantly different than those at t0. These results suggest that, after one or two 
days of incubation, the pool of bone samples is in a homogenous state of genetic expression at 
least for the tested genes. All the samples were then incubated 24h after extraction prior to the 1h 
mechanical test. 
 
 
 
Figure 3 - Relative gene expression of TGFB2, OPG and RANKL quantified by RT–PCR after 
0, 24 and 48 hours of incubation. The results are shown as 2-??CT values and plotted as 
MEAN±SEM of each individual experiment. 
 
Gene expression according to the mechanical stimulus 
The relative gene expression for the selected genes and mechanical stimulations are presented in 
Figure 4. RANKL was up-regulated in the compression and the micromotions groups. RANKL 
expression was up-regulated 2.8±0.9 fold in the compression group and up-regulated 8±2.8 
fold in the micromotions group when compared to control. The difference between static 
compression and control, and the between micromotions and control were significant, whereas 
there was a strong trend suggesting that the expression level between micromotion and static 
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compression were different. 
OPG expression was dramatically down-regulated 0.18±0.02 fold in the compression group 
and down-regulated 0.34±0.07 fold in the micromotions group when compared to control. The 
difference between static compression and control, micromotions and control, and micromotions 
and static compression were significant. 
TGFB2 expression was down-regulated 0.3±0.1 fold in the compression group and down-
regulated 0.2±0.08 fold in the micromotions group when compared to control. The difference 
between static compression and control and micromotions and control were not significant but 
the p-value (p=0.08) suggested a strong trend towards significant differences. 
IFNG expression was not significantly changed in the static compression group (1.4±0.4) and 
was down-regulated 0.29±0.05 fold in the micromotions group when compared to control. The 
difference between micromotions and control and micromotions and static compression were 
significant  
CSF-1 was not significantly affected in the static compression group (1±0.5) nor in the micro-
motion group (1±0.5) when compared to the control group.  
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Figure 4 – Relative gene expression of RANKL, OPG, IFNG, TGFB2 and RANKL:OPG 
expression ratio quantified by RT–PCR after one hour of incubation (control), 0.5MPa static 
compression or 0.5MPa static compression + 100μm micromotions (micromotions). The 
results are shown as 2--??CT values and plotted as MEAN±SEM of each individual experiment. 
Symbols: * (p<0.05 vs control), + (p<0.05 vs static compression), ? (trend at p<0.1 level vs 
control),    † (trend at p<0.1 level vs static compression). 
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Discussion  
A clinical study showed that up to 14% bone loss arose during the first three months after total 
hip arthroplasties [34]. In parallel, rapid early migrations have been detected by roentgen 
stereophotogrammetry in many asymptotic hips, often as early as 4 months postoperatively [11, 
18]. The migrations have been found to predict an increased risk of clinical loosening. The fate 
of an orthopedic implant seems then to occur at an early stage, probably before any wear 
particles are produced and is certainly related to mechanical factors. Micromotions at the bone-
implant interface are then ideal candidates to “explain” peri-implant bone resorption and were 
identified as key players in animal studies.  
However, no information thus far has confirmed these results for human bone, as the only 
information available are based on tissue retrieval obtained from failed implants, the last stage of 
the degeneration process [31]. Based on a unique ex vivo approach, the present study evaluates 
the micromotions effect on bone resorption for human samples and verifies if resorption could 
be initiated immediately after surgery, when no wear particles are part of the process. 
We hypothesized that micromotions could induce an up-regulation of genes involved in 
osteoclastic bone resorption. Therefore, we analyzed the expression ratios of the RANKL/OPG 
signaling system, as well as the expression ratios of TGFB2, IFNG and CSF-1. We used a 
control group, a static compression group and a micromotions group, mimicking the situation 
arising around femoral stems of hip implants during gait cycles [27]. 
RANKL is a critical factor for late stage oscteoclasts differentiation and activation. RANKL was 
shown to be expressed by osteoblasts after mechanical or hormonal stimulations [26]. OPG, the 
decoy receptor of RANKL produced by osteoblasts is a powerful inhibitor of osteoclasts 
formation in vivo and in vitro [30]. Our results show that micromotions and static compression 
dramatically increase RANKL expression suggesting that the number and the activity of 
osteoclasts at the implant surroundings are increased by micromotions and compression in 
normal gait conditions. We also observed a down-regulation of OPG expression after 
exposition to static compression alone or to micromotions suggesting that the balancing effect of 
RANKL by OPG is decreased. 
Experimental and mathematical evidences have recently shown that OPG and RANKL 
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expressions are regulated inversely in osteoblasts, and that bone remodeling rate is probably 
determined by the RANKL:OPG ratio [3, 12, 13]. Our results are in concordance with these 
observations: RANKL and OPG are expressed inversely after exposition to static compression 
alone or after static compression and micromotions, as discussed previously. We observed that 
the RANKL:OPG ratio is significantly increased ten fold by static compression and 
significantly more than twenty fold by static compression and micromotions, suggesting that 
micromotions are potent activators of high bone turnover rate. Our observations on the 
regulation of RANKL/OPG by static compression and micromotions suggest that the number of 
osteoclasts is enhanced, and bone turnover rate is increased in the periprosthetic area with 
normal gait cycle conditions. This might be one of the causes of the observed bone resorption 
around orthopedic implants.  
Osteoclasts and osteoblasts activities are strongly correlated in vivo, and an increased 
osteoclastic activity might induce an osteoblastic response. Similarly, micromotions may affect 
osteoblastic recruitment. Therefore we also analyzed the expression of bone formation signaling 
molecules such as TGFB2 and IFNG. TGFB2 is expressed by osteoblasts, and has contrasting 
effects on osteoblasts and osteoclasts. TGFB2 is a bone formation promoting molecule 
operating through chemotactic attraction of osteoblasts and enhancement of osteoblasts 
proliferation at the early stages of differentiation [9]. In cell culture, IFNG was shown to inhibit 
osteoblastic cell function [5] and potently inhibit osteoclasts formation. In bone explants, it 
inhibits osteoclasts differentiation [32]. We observed a down-regulation of TGFB2 after 
exposure to static compression alone and after static compression plus micromotions, 
suggesting that micromotions at the implant interface do not increase recruitment of osteoblasts 
through TGFB2 signaling. TGFB2 was shown to be a promoter of osteoclasts formation by 
increasing the sensitivity of progenitors to RANKL (through up-regulation of RANK in 
preosteoclastic cells) [25, 35]. TGFB2 can also inhibit osteoclasts formation through a down 
regulation of the RANKL:OPG ratio [35]. In our analysis, RANKL:OPG is increased while 
TGFß is decreased which is concordant. Our measures show that static compression and 
micromotions decrease IFNG expression by two thirds. The consequence is then difficult to 
interpret in the peri-implant situation, as the effect could be either a decrease of bone formation 
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through inhibition of osteoblastic function or a decrease of bone resorption through inhibition of 
osteoclastic differentiation. Further studies are needed to clarify the role of this molecule. 
The aim of the experimental setup used here was to simulate the mechanical situation at bone-
implant interfaces using ex vivo bone samples. The amplitude of the applied compression and 
micromotions were set to measured or calculated values. The drawbacks of this system are that 
the sample preparation procedures and ex vivo incubation certainly have biological consequences 
on bone cells functions despite we showed that at least there is an initial homogeneous level of 
gene expression between samples. We can then assume that we have a consistency of initial 
conditions in our experiment. However, certainly due to the inherent biological variability, we 
obtained variable quality of extracted RNA, which may affect the gene expression quantification. 
It has also to be mentioned that quantification of gene expression may only be part of the 
biological reaction to mechanical stimulus due to different post-transcriptional events. However, 
to our knowledge, no other experimental design allows one to study the effect of micromotions 
on the bone-implant interface with living human samples. These challenging technical difficulties 
were solved by a posteriori controls of RNA quality and variability of gene expression 
duplicates. More than 50% of the samples were discarded during these control procedures. It 
implied that paired-control statistical designs could not be use and that a large number of 
samples had to be processed to overcome the inter-specimen variations and to observe 
significant differences in the gene expressions. 
To conclude, our results suggest that micromotions at the bone-implant interface during normal 
gait cycles induce a rapid bone resorption response after only one hour, which occurs before any 
wear debris particles enter the system. These results confirm our initial hypothesis.  
Based on these results we proposed that blocking locally the osteoclastic resorption through the 
action of bisphosphonate might prevent the peri-implant osteolysis. The first results of our 
animal model of implants used as bisphosphonate delivery systems tend to confirm this idea [20, 
21].   
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Abstract 
The fixation of orthopedic implants depends strongly upon the initial stability of the implant. 
peri-implant bone resorbs shortly after the surgery. In a normal situation, this is shortly 
followed by new bone formation and implants fixation strengthening but if the initial stability 
is not reached, the resorption goes on and the implant fixation weakens, which leads to 
implant loosening. Studies with rats and dogs have shown that a solution to prevent peri-
implant resorption is to use deliver bisphosphonate at the implant surface.  
The present paper aims were, first, to develop a model of bone remodeling around an implant 
delivering bisphosphonate using our previously published results, second, to predict the 
bisphosphonate dose that would induce the maximal peri-implant bone density, and third to 
verify in vivo that peri-implant bone density is maximal with the calculated dose. 
The mathematical model consists of a bone remodeling equation and a drug diffusion 
equation. The change in bone density is driven by a mechanical stimulus and a drug stimulus. 
The drug stimulus function and the other numerical parameters were calculated from 
experimental data. The model predicted that a dose of 0.3?g of zoledronate on the implant 
would induce a maximal bone density. Implants with 0.3?g of zoledronate were implanted in 
rats’ femurs for 3, 6 and 9 weeks. We measured that peri-implant bone density was 4% 
greater with the calculated dose.  
The approach presented in this paper could be used in the design and analysis processes of 
experiments in local delivery of bisphosphonate.  
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Introduction  
The fate of orthopaedic implants seems to be principally determined at an early stage. Rapid 
early migrations of stems have been detected in many asymptotic hips, often as early as 4 
months postoperatively (Karrholm, Borssen et al. 1994). These early migrations have been 
related to an increased risk of clinical loosening. It has been reported that peri-implant bone 
resorbs during a short period after the surgery, probably in response to the surgically-induced 
trauma, inducing a weakening of the fixation (Venesmaa, et al., 2001). In normal healing 
conditions, the fixation strength increases after this initial weakening (Dhert, et al., 1998), but 
in pathologic conditions, the lack of initial fixation promotes osteolysis via bone-implant 
micromotions production, debris particulate formation and osteoclastic resorption 
(Stadelmann, et al., 2008). On the other hand, when a longer primary stability is achieved, the 
long-term survival of the implant is significantly improved (Karrholm, Borssen et al. 1994; 
Mjoberg 1997).  
 
Based on current knowledge regarding early biological events at the implant interface, it has 
been proposed to use bisphosphonate to improve the early implant fixation by preventing the 
post-op osteoclastic resorption (Horowitz and Gonzales, 1996). A recent clinical study 
showed that post-surgical systemic administration of clodronate prevents knee prosthesis 
migration (Hilding and Aspenberg, 2006). Animal studies have shown that bisphosphonate 
increases peri-implant bone density and shear strength of the bone implant interface in dogs 
(Jensen, et al., 2007) and in rats (Eberhardt, et al., 2007).  
 
Systemic administration of bisphosphonate presents several adverse effects, like fever, ulcers 
and osteonecrosis of the jaw (Dannemann, Gratz et al. 2007). Since bones are low-perfused 
organs, drugs diluted in blood stream have low probabilities to reach the required locations 
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with sufficient time or concentration to be effective. Therefore it seems ethically irresponsible 
to expose patients who have received orthopaedic implants to the risks induced by systemic 
administration of bisphosphonate, considering the benefits at the implant level are not 
ensured. 
 
To ensure the availability of bisphosphonate at the peri-implant area, where it is needed most, 
and to reduce the risks related to systemic administration, methods for local delivery have 
recently been addressed: these methods consist of grafting the drug onto the implant surface, 
by the mean of a carrier material, such as hydroxyapatite coating or multi-layers of 
fibrinogens. This technique avoids extra steps in the surgical protocol that are necessary for 
topical application (Jakobsen, et al., 2007), it ensures that bisphosphonate is restrained in the 
peri-prosthetic area, and allows a slower and more continuous release of the drug. The amount 
of drug applied can be delivered more efficiently and may be as low as 1/1000 of that used for 
an oral dose. The local delivery method proved its efficiency in different experimental 
situations. In rats, cortical screws releasing ibandronate and pamidronate increased the pullout 
force (Wermelin, et al., 2007). In rats, implants releasing zoledronate also increased the 
pullout force and the peri-implant bone density (Peter, Pioletti et al. 2005; Peter, Gauthier et 
al. 2006). According to these studies, the effect of bisphosphonate released from implants is 
non-linearly dose dependent.  
 
In order to calculate the optimal bisphosphonate dosage to obtain the best implant fixation, a 
biophysical theory of the events arising around an implant used for a local delivery of 
bisphosphonate is needed. Such a theory must relate bone remodeling to both the mechanical 
aspects of peri-implant situation and the effect of the bisphosphonate.  Most of the existing 
models of bone remodeling are mechanically driven e.g. (Huiskes, 1997). They are widely 
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used, yet it is outside the scope of this article to review these models. Few attempts exist to 
address the effect of systemic bisphosphonate using a model of remodeling (Hernandez, 
Beaupre et al. 2001; Pioletti and Rakotomanana 2004). However these attempts did not take 
into account the spatial diffusion of bisphosphonate when released from a local source. 
Therefore, the goals of the present study were triple: first, to develop a mathematical model of 
bone remodeling including mechanical stimulus as well as the stimulus of bisphosphonate 
diffusing from an implant; second, to identify the numerical parameters of the model from 
published data; third to validate the model by verifying its prediction in vivo. 
 
Materials and Methods 
In this section, we first present the development of a theoretical model of bone remodeling 
coupled with bisphosphonate diffusing from an implant. In the second part, the model 
parameters are identified with published experimental data. Finally, we present in vivo 
experiments using rats that provided data for the model validation. 
 
Theoretical developments  
The following developments were based on an existing bone model of remodeling previously 
developed in our lab (Terrier, et al., 2005). We extended the initial model by adding a new 
internal variable for the drug concentration. The bone density evolution law was adapted to 
include this new variable and finally we introduced a diffusion law for the drug. 
 
The initial model of remodeling, the local bone density ?  varies under the influence of a 
mechanical stimulus ? . The choice for this stimulus was the plastic yield stress of Hill 
(Rakotomanana, et al., 1992). According to this choice, it has been shown that the 
dependence of the stimulus in the density ?  could be written in the form ? =Y /? 4  (Terrier, et 
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al., 2005), where Y is a mechanical function that only depends on the stress, but may however 
depend on space and time through the stress. The bone density evolution law was 
characterized by three different regimes: resorption, equilibrium and densification, according 
to the stimulus level. In the present study, the extension of the initial model was limited to the 
densification regime. According to the evolution law (eq1), bone cells densify bone matrix 
when the stimulus exceeds a densification stimulus threshold ?d . 
 ?t? =? d (? ??d )          (eq1) 
The rate of densification is given by the constant ? d , which was determined from experiment 
in rats (Terrier, et al., 2005). 
The extension of the initial model consisted in adding the net effect of the drug as an 
imbalance of the remodeling process, resulting in a net gain in bone mass. This effect was 
introduced through a second stimulus, ?drug , called drug stimulus, which was defined as a 
function of a new internal variable, the local drug concentration ? . In a first step, the model 
was limited to the following hypothesis: (i) the drug stimulus depends only on the drug 
concentration (ii) the mechanical stimulus does not depend on the drug concentration, (iii) the 
bisphosphonate diffuses following Fick’s law of diffusion.  
The drug stimulus ?drug (?)  is expressed in [% change day-1], and the drug concentration ?  in 
[?g / mm3]. The rate of densification (eq1) becomes 
   ?t? =? d (
Y
? 4
??d ) +?drug (?)      (eq2) 
completed by drug diffusion 
   ?t? =? D??( )       (eq3) 
where D is the effective coefficient of diffusion, which takes into account the diffusion of the 
drug into bone marrow, and the tortuosity of cancellous bone.  
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Identification of the model’s parameters 
The unknown parameters of the extended model are the diffusion coefficient D, the 
mechanical function Y(x) and the drug stimulus function ?drug (?) . 
First we estimated experimentally that D ? 800  [?m2/day] with an experimental setup using 
C14-zoledronate diffusing through trabecular bone sections (Peter, 2004). 
To identify the other numerical parameters, we used previously published bone density 
profiles measured around drug-releasing implants (Peter, Pioletti et al. 2005). These profiles 
were obtained with five different doses of zoledronate (0, 0.2, 2.1, 8, 16?g/implant) grafted 
onto the hydroxyapatite coating of cylindrical titanium implants in rat condyles at 3 weeks 
post-op. We simplified the system of equations (eq2 and eq3) with regards to this particular 
experimental setup, with the following assumptions: First, we reduced the system to a one-
dimensional axisymmetric geometry where x is the distance from the coating. Second we 
idealized the boundary conditions by assuming that (i) the hydroxyapatite coating is an 
infinite source of bisphosphonate, i.e. ?(x = 0,t) ??0, and (ii) at 2mm from the coating the 
drug concentration is null i.e. ?(x = 2000,t) ? 0  (Figure 1). 
 
According to these assumptions we estimated the mechanical parameter, Y (x) , by solving the 
evolution equation (eq2) for the control group without drug stimulus. In the following 
calculations, we further assumed that Y (x)  is the same for all groups, which is reasonable 
since it only represents the stress state. Finally, we calculated the drug stimulus ?drug (?)  from 
the bone density at the coating surface, where drug concentrations can be assumed to be 
constant and equal to that of the coating, for the five different drug concentrations used in the 
in vivo data (Peter, Pioletti et al. 2005). The validity of these assumptions is discussed in the 
last section. 
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Figure 1. Simplified scheme of the experimental system: the titanium implant (Ti) is coated 
with a thin layer of hydroxyapatite (HA). Bisphosphonate molecules (stars) initially loaded in 
the hydroxyapatite coating are slowly released, diffuse in the peri-implant trabecular bone 
(Tb) and influence the remodeling locally. The bisphosphonate concentration and the bone 
density are functions of the distance x from the coating. 
 
The bone density was then calculated from the model as a function of the distance from the 
coating and is represented in Figure 2. As seen in this figure, the theoretical density profiles 
calculated from the model are very similar to the experimental data. The error between data 
and model was estimated as the mean relative difference in bone density for 0 < x < 150?m. 
The measured errors were smaller than 5% for each BP concentration. Computations were 
processed with custom-made routines of Mathematica (Wolfram Research, USA).  
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Figure. 2 - (a) Shows Y(x) as a function of x as calculated from the data (points) and the 
continuous interpolation used for numerical computations (line). (b) Shows the drug stimulus 
as a function of drug concentration (points), and the continuous interpolation used for 
numerical computations (line). (c) Shows bone density (BS/TS) as a function of the distance 
from coating: experimental (points) and model (lines) for the different drug concentrations. 
 
Validation of the model 
The verification of the model was done in two steps. First, we evaluated the bisphosphonate 
dose, which theoretically induces the maximal peri-implant bone density. We refer to this 
dose as the “optimal dose” in the following pages. In the second step, we verified that this 
optimal dose induced in vivo the maximal peri-implant bone density in a rat model. The in 
vivo methods used in this part were adapted from (Peter, Pioletti et al. 2005).  
 
Estimation of the optimal concentration 
To calculate the optimal drug dose, we solved the theoretical model, with zoledronate 
concentration as the variable, to maximize the bone density over a thickness of 100?m from 
the coating: Max
?
?(x,?)dx
0
100μm
? , and we found that ? opt = 0.044?g/mm3 corresponding to 
0.3?g/implant. With this drug dose we calculated that the average bone density in the 100?m 
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proximity of the implant would be BS/TS = 63%, i.e. 2% greater than the highest density 
measured so far with 2.1?g/implant. 
 
Implants 
Twelve Titanium alloy cylinders (diameter 3 mm; length 5 mm) were plasma-coated with 
hydroxyapatite and then six implants were soaked in aqueous solutions of 3 10-6 and six 
implants in 2.25 10-5 mol L-1 of zoledronate (Novartis Pharmaceuticals AG, Switzerland) for 
48h. The amount of zoledronate loaded onto the implants was calculated to be respectively 
0.3 ?g and 2.1 ?g.  
 
Rats 
Twelve female 6-month-old Wistar rats were used in this experiment. The animals had free 
access to normal diet. The animals were randomly separated into six different groups 
representing the two zoledronate doses: 0.3 and 2.1 ?g/implant and three time points: 3, 6 and 
9 weeks (Table 1). Each rat received one implant in a femoral condyle.   
 
N animals 3w 6w 9w 
0.3?g 2 2 2 
2.1?g 2 2 2 
 
Table 1 - Number of animal per group 
 
Surgery 
The local Ethical Committee for Animal studies of the National Veterinary School of Nantes 
approved the protocol for the animal experiment. Animals were kept at the Experimental 
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Surgery Laboratory of the Nantes University according to European Community guidelines 
for the care and use of laboratory animals (DE86/609/CEE). 
Surgical procedures were conducted under general anaesthesia. The implantations were 
performed at the distal end of the femurs, at the epiphysometaphyseal junction. The lateral 
condyle was exposed and drilled perpendicularly to the long axis of the femur with two 
successive bits (2.2 and 2.8 mm in diameter) on a low-speed rotative dental handpiece and 
under sterile saline irrigation. The implant was then gently inserted into the cavity under 
digital pressure. Articular and cutaneous tissues were closed in two separate layers. After 
surgery, all the animals were allowed to move freely in their cages. Animals were killed 3, 6 
or 9 weeks after implantation by intracardiac injection of overdosed sodium pentobarbital 
under general anaesthesia. 
 
Preparation for Imaging 
The femoral ends were then immediately dissected, fixed in glutaraldehyde solution, and 
stored in a 4% paraformaldehyde, 0.1% glutaraldehyde in 0.08 M cacodylate buffer. The 
sample was dehydrated in a series of alcohol solutions. For the impregnation, the sample was 
soaked in a mixture of 50% alcohol 1008 and 50% methyl methacrylate MMA (Fluka 
Chemika, Sigma Aldrich Chemie Gmbh, Steinheim, Germany) during 24 h then in pure 
MMA during 24 h. For the inclusion, the sample was soaked during 2 h under vacuum in a 
solution containing 90% MMA, 10% dibutylphtalate and 1% benzoyl peroxide (Fluka 
Chemika), then soaked in the same solution but enhanced by a polymerization activator (N,N-
dimethylp-toluidine) (Fluka Chemika). The polymerization took place at -20°C during 48 h. 
Three to four slices of 300?m thick perpendicular to the implant were cut from each sample, 
using a Microtome saw 1600 (Leica, Nussloch, Germany) diamond saw.  
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Scanning Electron Microscopy 
The slices were carbon-coated. The samples were then observed in a JEOL JSM 6300 
scanning electron microscope (JEOL, Tokyo, Japan) using the backscattered electron detector 
allowing distinguishing mineralized bone from soft tissue. Then, these images were used to 
measure the bone density as a function of the distance from the coating. The implant surface 
and trabecular bone regions were defined manually on each image. To distinguish bone from 
other tissues: pixels with graylevel between 0 and 62 were considered as calcified bone, while 
those with graylevel from 63 to 255 were considered as other tissues. We defined successive 
regions of interests inside the trabecular bone in the form of series of ten 20?m thick arcs co-
centered with the implant. In each arc, the number of bone pixels was counted and the bone 
density was defined as bone pixels divided by total pixels in the arc (BS/TS), using custom 
algorithms developed with ImageProcessing for Mathematica.  
 
Statistics 
The number of slices per group was accounted for as repetition of the density measurement of 
the same group. Student-t test was used to determine the statistical significance of the results.  
 
Results 
In vivo verification of model’s predictions 
The model predicted that a drug dose of 0.3 ?g/implant maximizes bone density within 
100?m layer around the implant. To verify this prediction, bone density was measured in vivo 
with 0.3 ?g/implant and 2.1 ?g/implant zoledronate at 3, 6 and 9 weeks in rat condyles. These 
measures were compared to previous measures obtained by Peter et al. with 0, 0.2, 2.1, 8 and 
16 ?g zoledronate/implant from (Peter, Pioletti et al. 2005).  
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One rat in the 3 weeks - 2.1 ?g zoledronate group and one rat in the 9weeks-0.3?g-
zoledronate group were excluded from further analysis, as, for unknown reasons, the implant 
was not integrated into bone. A total of thirty-three slices were analyzed (Table 2). 
 
Number of slices 3w 6w 9w 
0.3?g 6 8 3 
2.1?g 3 6 6 
 
Table 2 - Number of slices for imaging per group 
 
At three weeks, the model’s predictions were verified. The mean bone density of the group 
with optimal zoledronate dose was 4% greater than the highest bone density obtained so far in 
our previously published results (Figure 3a), however this difference of density with the 2.1?g 
group was not significant (p=0.09). The mean bone density with 2.1?g zoledronate / implant 
was in the range of our previous data. The difference in bone density between the 
0.3?g/implant group and the 2.1 ?g/implant group observed at 3 weeks, was no longer 
observed at 6 and 9 weeks (Figure 3b).  
 
Evolution of the integration of the implant 
The SEM observations confirmed implant integration comparable to that previously described 
(Fig. 4a). The hydroxyapatite coating evolved at the different time points after implantation. 
At 3 weeks, the bone was in contact with the coating surface, but there were no signs of 
resorption in the coating and almost no bone entering the coating (Fig. 4b). At 6 weeks, the 
first signs of resorption appeared in the coating. Approximately half of the thickness of the 
coating had been resorbed and lacunae could be observed in the coating (Fig. 4c). At 9 weeks, 
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most of the coating had been resorbed and newly formed bone was in contact with the 
titanium surface. Lacunae were still present inside the coating and some speckles of bone 
grew directly from the implant surface (Fig. 4d). 
 
 
Figure 3 - (a) Mean peri-bone density (BS/TS) in the first 100?m layer. The dark bars were 
adapted from (Peter et al.) the light bar represents the group with 0.3 ?g/implant 
zoledronate. (b) Evolution of mean bone density (BS/TS) at 3 6 and 9 weeks post-op.  
 
 Discussion 
The principal aims of this projects were first, to develop a theoretical framework of bone 
remodeling influenced by local release of bisphosphonate; second, to identify the numerical 
parameters of the model and third, to verify the model’s predictions in vivo.  
 
The development of the model consisted of adding the drug concentration as a new internal 
variable to an existing model of remodeling, completed by a function relating the drug 
concentration to the remodeling stimulus. The parameters appearing in this new model were 
identified from our previously published experimental data (Peter, et al., 2005). Next we 
solved this model to predict that a dose of 0.3?g of zoledronate grafted on the implant coating 
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would maximize the peri-implant bone density. This prediction was finally confirmed 
experimentally: with this calculated dose, the bone density was maximal, compared to other 
doses, at 3, 6 and 9 weeks post-op. 
 
 
Figure 4 - SEM pictures of implanted condyles: panel (a) shows the bone structure of a 
condyle implanted with HA-coated implant containing 2.1?g zoledronate at 3 weeks. The 
implant integration is qualitatively similar to previously published results. Panel (b) shows a 
detail of the bone-coating interface at 3 weeks. Bone is not yet entering the coating. Panel (c) 
shows the interface at 6 weeks with the first signs of coating resorption, and panel (d) shows 
the interface at 9 weeks with more than 50% of the coating resorbed.    
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 The intensity of the effect of bisphosphonate is dose dependent. The theoretical framework 
developed here shows that the interpretation of bone density profiles has to take into account 
the mechanical situation, the drug diffusion and the effect of drug on the remodeling balance, 
modeled here by the drug stimulus ?drug .  
The drug stimulus function is the key point of the model. It can be interpreted as the signature 
of the drug in a particular animal model. The shape of this function reflects that the drug 
induces the imbalance of the remodeling process after the decrease of osteoclast activity. The 
shape of the function is concordant with what is observed in vitro: bisphosphonates, like most 
drugs, have a range of concentration with beneficial effects but can produce adverse effects at 
higher doses (Fleisch, 2002). 
The model presented here is based on several hypotheses, which were consistent with the 
experimental situation addressed. We assumed that the model of a cylindrical implant could 
be reduced to a one-dimensional geometry. This assumption is relevant in our situation as we 
analyzed only the average density of a very thin layer of bone and we were not interested in 
histomorphometry aspects. Moreover the analyzed slices were not taken from the extremities 
of the implants, which are in the cortical regions of the condyles. 
We identified from experimental data that the loading function Y(x) increased significantly 
near the implant surface. This certainly reflects the mechanical stress following press-fit 
insertion and spring-back effect of bone (Kold, et al., 2003). With a different surgical 
protocol, the stress distribution would certainly be different, and Y(x) would have to be re-
calculated. 
 
In the resolution of our model, we simplified the boundary conditions: we set the coating as 
an infinite source of drug at constant concentration. The relevance of this assumption for 
short-term studies was confirmed by the SEM observations: at three weeks, the coating was 
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indeed not significantly resorbed. It was probably still protected from osteoclastic resorption 
by its content in bisphosphonate. This is concordant with the very low release rate of 
zoledronate by hydroxyapatite (Roussiere, Montavon et al. 2005). However, this simplifying 
assumption cannot be used for long-term studies: we observed that the hydroxyapatite coating 
was partially degraded at 6 weeks, and this degradation continued at 9 weeks. The 
bisphosphonate concentration in the coating then certainly decreases significantly after 3 
weeks. With the second boundary condition, we assumed that the drug concentration is 
negligible at 2mm from the implant surface, which corresponds to the growth plate and the 
bone marrow. Since these tissues are well perfused, the drug is certainly diluted into the blood 
volume. 
 
The observed degradation of the coating at 6 and 9 weeks, and the lacunae in resorbed areas 
might reflect the presence of osteocytes in the newly formed bone-implant interface. This is a 
sign of good implant integration at mid- and long-term post-op with the optimal zoledronate 
concentration. However, more histology would be needed to confirm this observation. 
 
Our results are certainly dependent on the choice of the drug and on the animal model. In the 
present study, we determined the drug stimulus function for zoledronate in rats. To extend the 
model predictions to other active molecules or other animals, the first step would be to 
determine the drug stimulus function, which we called the drug signature, with the specific 
drug using the specific animal model. To our knowledge, none of the required data for such 
identification with other animals or with different drugs has been published. 
 
Only a limited number of animals were used in the experimental part of this project. The main 
objective of this project was to compare the theoretical model’s outcomes to an in vivo 
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situation. The experiments were therefore designed to validate the model rather than to 
provide new statistically significant experimental results, which would have required a much 
larger number of animals.  
 
The principal objective of coating implants with bisphosphonate for local delivery is to 
increase the fixation of the implant. The pullout force is somehow related to peri-implant 
bone density (Peter, et al., 2005), but other factors, such as bone quality, also have an 
influence. A mathematical relationship between histomorphometry of bone and its mechanical 
capacity to resist pullout has yet to be determined (Jakobsen, et al., 2006). Thus, the 
mathematical model presented here only predicts bone density. More work will be needed to 
link bone density to implant fixation strength.  
One of the most important challenges associated to orthopaedic implants is to obtain 
sufficient early fixation to ensure long-term stability, for patients of variable age, daily 
activity level or bone quality. Although several studies have shown that implants delivering 
bisphosphonate improve this fixation, the bisphosphonate molecule, the dose, or the animal 
model have always been chosen empirically. The theoretical framework presented here could 
be of great interest to further analyze and compare the different experimental results.  
Moreover such comparisons would be particularly helpful to design future animal or clinical 
studies. In the long term, mathematical framework could be necessary to design optimal 
orthopaedic implants.  
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Abstract 
It is a clinical challenge to obtain a sufficient orthopedic implant fixation in weak 
osteoporotic bone.  When the primary implant fixation is poor, micromotions occur at the 
bone-implant interface, activating osteoclasts, which leads to implant loosening.  
Bisphosphonate can be used to prevent the osteoclastic response, but when administered 
systemically its bioavailability is low and the time it takes for the drug to reach the 
periprosthetic bone may be a limiting factor. Recent data has shown that delivering 
bisphosphonate locally from the implant surface could be an interesting solution. Local 
bisphosphonate delivery increased periprosthetic bone density, which leads to a stronger 
implant fixation, as demonstrated in rats by the increased implant pullout force. The aim of 
the present study was to verify the positive effect on periprosthetic bone remodeling of local 
bisphosphonate delivery in an osteoporotic sheep model. Four implants coated with 
zoledronate and two control implants were inserted in the femoral condyle of ovariectomized 
sheep for 4 weeks.  The bone at the implant surface was 50% higher in the zoledronate-group 
compared to control group. This effect was significant up to a distance of 400?m from the 
implant surface. The presented results are similar to what was observed in the osteoporotic rat 
model, this suggests that the concept of releasing zoledronate locally from the implant to 
increase the implant fixation is not species specific. The results of this trial study support the 
claim that local zoledronate could increase the fixation of an implant in weak bone.  
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Introduction 
A current clinical challenge in the field of Orthopedics is to obtain a stable implant fixation in 
weak osteoporotic bone. The fixation of orthopedic implants in bone relies strongly upon the 
initial stability of the implant. When the initial stability is not achieved, micromotions occur 
at the bone implant interface (Mandell et al., 2004; Ramaniraka et al., 2000). The 
micromotions then activate an osteoclastic response (Stadelmann et al., 2008), which results 
in periprosthetic osteolysis and later implant migration and wear (Karrholm et al., 1994). 
Both particulate formation from implant wear and implant migration have been shown to be 
associated with increased implant failure rate (Clarke et al., 1992; Horikoshi et al., 1994). In 
the case of osteoporotic patients, this early phase is particularly delicate as the bone is already 
weak at the time of surgery. In this case, the resorption of a small amount of bone near the 
implant may induce a dramatic decrease in early fixation, accelerating the failure process. 
Bisphosphonate can be used to reduce periprosthetic osteolysis allowing orthopedic implants 
to achieve a stronger primary fixation (Hilding et al., 2000). Bisphosphonate molecules 
inhibit osteoclastic activity, and therefore are widely used to treat patients with osteoporosis 
(Bone et al., 2004; Fleisch, 2002). However, when administered orally, the bioavailability of 
bisphosphonate is generally very low, and its local delivery can be further delayed in regions 
of the skeleton with low blood perfusion, for example the femoral neck. Recent clinical 
studies have shown that systemic bisphosphonate treatment following prosthesis implantation 
reduced periprosthetic bone loss only after 3 months (Nehme et al., 2003; Venesmaa et al., 
2001b), while significant bone loss arises during this initial period of 3 months (Venesmaa et 
al., 2001a). A solution to accelerate the local availability of bisphosphonate at the implant 
location is to deliver the drug locally. This insures the immediate presence of drug molecules 
at the implant location regardless of the local blood perfusion.   
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Implants with local delivery of bisphosphonate have been studied previously in small animal 
models and the results are generally encouraging: In rats, hydroxyapatite coated implants 
releasing zoledronate increased periprosthetic bone density and the pullout force (Peter et al., 
2005); fibrin coated cortical screws releasing ibandronate and pamidronate increased the 
pullout force (Wermelin et al., 2007). Moreover, in dog ulna, Tanzer et al. showed that local 
elution of zoledronate can cause substantial bone augmentation around and within porous 
tantalum implants (Tanzer et al., 2005). Concerning the osteoporotic bone case, hydroxapatite 
coated implants releasing zoledronate increased pullout force and periprosthetic bone density, 
compared to control implants in osteoporotic rats (Peter et al., 2006). 
Many differences, such as mineral density, healing capacity or the response to mechanical 
stimuli, exist in the bone metabolism of small animals when compared to that of humans 
(Egermann et al., 2005; Holy et al., 2000). Therefore it is questionable to extrapolate the in 
vivo results of small animals into the specific clinical situation of osteoporotic patients 
without pre-clinical tests in a large animal (Buma et al., 2004). To our knowledge, no data 
exists concerning local delivery of bisphophonate to increased fixation strength of an implant 
in a large osteoporotic animal model. 
Therefore the aim of the present study was to verify the efficacy of local bisphosphonate 
delivery to increase the periprosthetic bone density in an osteoporotic sheep model (Turner, 
2002).  
 
Material and Methods 
Implants 
Six Titanium alloy (TA6V) cylinders (diameter 3 mm; length 5 mm) were plasma-coated with 
hydroxyapatite (thickness: 20 ?m; crystallinity index 62%). Two samples were used as 
controls, while the remaining 4 samples were soaked for 48h in 5ml ultrapure water solutions 
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of 2.25 10-5 mol L-1 of Zoledronate (1-hydroxy-2-[(1H-imidazole-1-yl)ethylidene] 1-
bisphosphonic acid disodium salt) supplied by Novartis Pharmaceuticals AG, Switzerland. 
The amount of zoledronate loaded onto the implants was calculated to be 2.1 ?g for each 
implant (Josse et al., 2004). 
 
Animals and surgical procedures 
Animal handling and surgical procedures were conducted according to the European 
Community Guidelines for the care and use of laboratory animals (DE 86/609/CEE) and 
approved by the local ethical committee at the Nantes Veterinary School. Three adult female 
vendeen sheep with an average body weight of 55 kg were used in this study. Six months 
prior to the study, animals had been neutered by ovariectomy to induce osteoporosis. 
Subsequent bone changes were investigated on iliac crest bone biopsies. A control biopsy was 
harvested on the day of ovariectomy and was compared with a bone sample from the 
contralateral iliac crest harvested 6 months later on the day of implantation. Changes in the 
microarchitecture of iliac crest biopsies were investigated through 3D microtomography 
analysis. 
The tested cylinders were implanted bilaterally for 4 weeks at the distal femoral end of the 3 
mature female sheep. The first animal had two control implants. The second and third animals 
had two zoledronate coated implants. After 2 weeks of acclimatization, general anesthesia 
was induced using an intravenous injection of 4 mg/kg of propofol (Rapinovet®, Shering-
Plough, France) and 0.1 mg/kg of diazepam (Valium®, Roche, France). Anesthesia was 
maintained for surgery with a gas mixture of isoflurane (1.5 %), and oxygen (98.5 %). A 
single dose of morphine (0.5 mg/kg) was injected subcutaneously at the beginning of the 
surgery as an analgesic. After shaving and disinfection (Vetedine®, Vetoquinol, Lure, 
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France) of the knee, a stifle arthrotomy was performed to expose the distal lateral condyle of 
the femur.  
A cylindrical osseous defect (3 mm in diameter and 6 mm length) was created on the distal 
femoral epiphysis using a motor-driven drill (Aesculap, Tuttlingen, Germany). After saline 
irrigation, the osseous cavity was carefully dried and filled with the coated cylinder. 
The joint capsule was closed with non-absorbable sutures (Prolene® 2-0, Ethicon, France). 
The subcutaneous tissues and skin were closed in different layers using absorbable sutures 
(Polysorb® 2-0, TycoHealthcare, France). Finally, the surgical wound was covered with an 
adhesive bandage. Both hind limbs were operated, giving 2 tested implants per animal. At the 
end of surgery, animals received an injection of meloxicam to complete analgesia (Métacam 
Bovin®, Boehringer Ingelheim, Germany) but did not receive any postoperative antibiotics. 
The procedure was repeated on the contra lateral side. 
After 4 weeks, general anesthesia was induced by a mixed injection of ketamine 
(Imalgène®1000, Merial, France) and xylazine (Rompun®, Bayer, France) and the animals 
were euthanasized by intravenous injection of 20 ml of pentobarbital (Doléthal®, Vétoquinol 
S.A., France) through a catheter placed into the jugular vein. The femoral extremities were 
then dissected from the surrounding soft tissues and immediately placed in a 10 % neutral 
formol solution.  
 
Preparation for imaging 
The femoral distal ends were then immediately dissected, fixed in glutaraldehyde solution, 
and stored in a 4% paraformaldehyde, 0.1% glutaraldehyde in 0.08 M cacodylate buffer. 
Using a handsaw, the condyle was sawed off 1 cm above the implant. The sample was 
dehydrated in a series of alcohol solutions. The first impregnation step was to soak the sample 
in a mixture of 50% alcohol 1008 and 50% methyl methacrylate MMA (Fluka Chemika, 
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Sigma Aldrich Chemie Gmbh, Steinheim, Germany) during 24 hours. The second 
impregnation step was to soak the sample in pure MMA during 24 hours. The first inclusion 
step was to soak the dehydrated sample during 2 hours under vacuum in a solution containing 
90% MMA, 10% dibutylphtalate (Fluka Chemika) and 1% benzoyl peroxide (Fluka 
Chemika). The sample was then removed from the solution and soaked in the same solution 
but enhanced by a polymerization activator (N,N-dimethylp-toluidine) (Fluka Chemika). The 
polymerization took place at -20°C and was complete after 48 hours. Two to four slices of 
300?m thick were cut from each sample, using a Microtome 1600 (Leica, Nussloch, 
Germany) diamond saw. The cutting plane was perpendicular to the implant. 
 
Scanning Electron Microscopy 
Slices were carbon-coated and observed using a JEOL JSM 6300 scanning electron 
microscope (SEM) (JEOL, Tokyo, Japan) using the backscattered electron detector, allowing 
mineralized bone to be distinguished from soft tissue.  
Then, SEM images were used to measure the bone density as a function of the distance from 
the coating. The implant surface and trabecular bone regions were defined manually on each 
image. The implant center and radius were then calculated by least square fitting of a circle 
onto the implant surface. A threshold was applied to the image in order to distinct bone from 
other tissues: pixels with a graylevel between 0 and 62 were considered as calcified bone, 
while those with a graylevel from 63 to 255 were considered as other tissues. We defined 
successive regions of interests inside the trabecular bone in the form of series of ten 20?m 
thick arcs co-centered with the implant. In each arc, the number of bone pixels was counted 
and the bone surface fraction (B.Ar/T.Ar) was defined as bone pixels divided by total pixels 
in the arc, using custom algorithms developed with Image Processing for Mathematica 
(Figure 1).  
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Figure 1: Schematic of the method used to determine the bone surface fraction profile. At a 
distance x from the coating surface, a region of interest (ROI) was defined as an annulus of 
20?m thickness co-centered with the implant of radius R+x, where R is the implant radius. 
Then the number of bone pixels inside the ROI (blue pixels) was divided by the total number 
of pixels in the ROI (blue+yellow pixels). The distance x was incremented from 0 to 1mm in 
steps of 20?m.  
 
Statistics 
The number of slices per group was accounted for as repetition of the density measurement of 
the same group. Student-t test was used to determine the statistical significance of the results. 
Wilcoxon test was used to identify the significant changes of microstructural properties in the 
iliac crest biopsies.  
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Results 
A total of 19 slices (6 control, 13 zoledronate-loaded) were processed (Table 1).  
 
 Control Zoledronate 
Sheep 1 2 
Implants 2 4 
Slices 6 13 
 
Table 1: Number of animals, implants and slices per group 
 
Osteoporosis induction 
Significant microstructural evolutions were measured on the iliac crest biopsies (Figure 2). 
The bone volume fraction (BV/TV) decreased by 30% at six months post-ovariectomy. While 
trabecular thickness (Tb.Th), trabecular number (Tb.N) and trabecular separation (Tb.Sp) 
decreased by 11%, 19%, and increased by 14% respectively; the structural model index (SMI) 
was not significantly affected (Table 2). 
 
Implant integration 
The implant integration was verified qualitatively during backscattered electron microscopy 
imaging. We observed homogenous bone-implant contact as well as new bone formation 
along the coating surface. Lacunae were observed in the bone speckles growing from the 
coating. Different levels of mineralization were observed in the newly formed bone. The 
coating was partially resorbed, and new bone was observed in the resorption zones (Figure 3).  
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Figure 2: Three-dimensional microtomographic description of iliac crest biopsies 
microarchitecture (a) before ovariectomy and (b) 6 months after ovariectomy. The difference 
illustrates the induction of osteoporosis. 
 
 Control OVX Evolution (%) 
BV/TV (%) 19.0 ± 3.3 13,3 ± 1.3 -30 
Tb.Th (μm) 144.1 ± 15.8 128,0 ± 11.1 -11 
Tb.N (10-3/μm) 1.32 ± 0.14 1,07 ± 0.15 -19 
Tb.Sp (μm) 683 ± 56 783 ± 66 +14 
SMI 0,86 ± 0.23 0,90 ± 0.18  
   
Table 2: Microstructure data of iliac crests biopsies obtained before ovariectomy (Control) 
and the day of implantation (OVX), data as Mean±SD. The evolution column shows 
significant changes (p<0.05).  The relative evolution of bone architecture parameters 
emphasise osteoporosis induction. 
 95
 
Figure 3: SEM pictures of three slices at magnifications of 50? (a, b) and 300? (b). (a) Local 
bone structure of a condyle implanted with an HA-coated implant (i) containing 2.1?g 
zoledronate. (b) Local bone structure of a condyle implanted with an control implant (i).  
(c) Details of the osseointegration of an zoledronate-implant (i) shows bone growth into 
resorbed spaces of the coating. Osseointergation in control implants was qualitatively 
similar. 
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Bone surface fraction 
The bone surface fraction (B.Ar/T.Ar) in a 20?m-thick layer around the implant was 50% 
higher in the zoledronate group compared to the control group (B.Ar/T.Ar=0.45±0.08 for the 
zoledronate group, 0.30±0.07 for the control group, p<0.05). B.Ar/T.Ar of the zoledronate 
group decreased from 0.45±0.08 at the coating surface to 0.30±0.05 at 800?m from the 
coating, while the profile of the control group was almost constant (figure 4a). The difference 
between B.Ar/T.Ar of the zoledronate group and the control group was significant up to 
400?m from the coating (figure 4b). The total bone area (B.Ar) in 400?m-thick layer around 
the implant was 10% greater in zoledronate group compared to control group (p<0.05) (figure 
4c).  
 
Figure 4: (a) Bone surface fraction (Mean±SEM) as a function of the distance from the 
implant coating. (b) Student test’s p-value of B.Ar/T.Ar comparison between zoledronate-
group and control-group as a function of the distance from the coating: the effect of local 
zoledronate is significant up to 400?m from the coating. (c) Total periprosthetic bone surface 
in a 400?m thick layer around the implant for zoledronate group and control group 
(Mean±SD, *: P<0.05 compared to control, SD were calculated from the number of slices per 
group which were accounted for as repetition of the density measurement of the same group). 
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Discussion 
Implants locally delivering bisphosphonate have been showen to increase periprosthetic bone 
density and pullout forces in previous studies using rat models (Kajiwara et al., 2005; 
Wermelin et al., 2007). However the bone metabolism of healing and remodeling in rats is 
different than in humans (Buma et al., 2004; Egermann et al., 2005). Therefore a large animal 
study was necessary to validate these results for later applications to human patients with 
osteoporotic bone. In this study, our aim was to use the osteoporotic sheep model to verify the 
efficacy of locally delivering zoledronate from an orthopedic implant to increase the 
periprosthetic bone density.  
Our results showed that B.Ar/T.Ar in a 20?m layer was increased by 50% in the locally 
delivered-zoledronate group compared to the control group in osteoporotic sheep. The effect 
of local delivery of zoledronate on B.Ar/T.Ar was significant up to 400?m distance from the 
implant. The mean B.Ar/T.Ar in the 400?m region around the implant was increased by 10% 
in the zoledronate-group compared to the control group.  
The implant and dose of zoledronate used in the sheep condyles are identical to those 
implanted for three weeks in previous rat and OVX rat models (Peter et al., 2006; Peter et al., 
2005). The experimental timeline for the sheep was chosen to be four weeks as to compensate 
for the possibility of a slower remodeling rate in larger animals. When the results of these 
different models were compared (Table 3), we observed: In non-osteoporotic rats, zoledronate 
coated implants induced an increase of 43% of B.Ar/T.Ar at the implant surface, while in 
osteoporotic rats the increase was 20% at 3 weeks post-surgery. In the present osteoporotic 
sheep model, at 4 weeks post-surgery, we observed an increase of 50%, which is significantly 
greater than the effect in rats. Moreover, the distance from the implant over which the effect 
of zoledronate is significant is five times greater in osteoporotic sheep than in osteoporotic 
rats.  
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 B.Ar/T.Ar 
Control 
B.Ar/T.Ar 
Zoledronate 
Relative 
Increase 
Distance of 
the effect 
Rats 0.48±0.04 0.69±0.03 43% 250?m 
OVX rats 0.46±0.03 0.55±0.03 20% 70?m 
OVX sheep 0.30±0.07 0.45±0.08 50% 400?m 
 
Table 3: Comparison of the effect of 2.1?g zoledronate / implant versus control on 
periprosthetic B.Ar/T.Ar in a 20?m layer, and distance of the effect from the implant. Rats 
and osteoporotic rats data adapted from (Peter et al., 2005) and (Peter et al., 2006) 
respectively. 
 
The observed difference cannot be explained simply with this data. It can be related to 
prolongation of one week in the post-surgery delay, to an enhanced reaction of sheep bone 
cells to zoledronate, or to the initial difference in bone density. Despite the questions that 
remain unanswered, these results show that a small dose of zoledronate delivered locally in 
osteoporotic sheep bone efficiently increases periprosthetic bone density in a way similar to 
what was previously observed in rats.  
This result is concordant with the very recent study of Goodship et al., in which intravenous 
administration of zoledronate pre- peri- and postsurgery reduced periprosthetic cortical 
osteopenia in a sheep model of hip replacement (Goodship et al., 2008). Therefore, 
zoledronate treatments seem to have a benefic action on periprosthetic bone, cortical or 
trabecular.   
The goal of local bisphosphonate release is to increase the implant fixation strength, but a 
complete pullout study would have required supplementary animals. Pullout force is mainly 
influenced by bone density in a thin layer of bone, extending 20?m radially from the implant 
(Peter et al., 2005). In osteoporotic rats an increase of 20% of bone volume fraction in the 
20?m layer induced nearly a 100% increase in pullout force (175±70N with 2.1?g compared 
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to 90±30N for controls). However, the exact effect on pullout force in the sheep model cannot 
be calculated from rat models, as the scale of bone trabeculae and the bone density are very 
different in these species. But, with more than 2-fold increase in bone volume fraction in the 
20?m layer, it is likely that an increase in pullout force would be observed as well in the 
present study. 
Zoledronate, like other bisphosphonates, has been shown to limit bone loss in patients with 
osteoporosis (Glatt, 2001), while also inducing a beneficial impact on microarchitectural 
properties of trabecular bone (Poole et al., 2007; Recker et al., 2008). In the present study we 
did not assess other microarchitectural properties of periprosthetic bone than B.Ar/T.Ar. 
However some of these properties, such as the bone volume fraction are mathematically 
linked to B.Ar/T.Ar (Parfitt et al., 1987; Revell, 1983). 
 
Clinical relevance of the study 
The clinical aim of coating orthopedic implants with zoledronate is to improve the fixation of 
orthopedic implants in patients with weak bone. Benefits of zoledronate local delivery were 
previously observed in osteoporotic rats. The present study further extended these results to a 
large animal model. The measured increase of periprosthetic bone density supported that local 
zoledronate delivery significantly improves the implant fixation in osteoporotic sheep.   
 
To further validate the use of implants with local zoledronate delivery, the next set of 
experiments should be performed with full load bearing implants to quantify the combined 
effects of mechanical stimulus and zoledronate release to the response of periprosthetic bone. 
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Discussion with reviewers 
Reviewers: In the absence of extensive clinical data, the relative practical benefits of local 
versus systemic bisphosphonate delivery are still debatable.  Whilst local delivery from a 
coated implant may reduce the risk of side effects, a patient requiring an implant is likely to 
have osteoporosis at other sites and would thus benefit from systemic drug exposure.  
Moreover, after a surgical intervention to implant a prosthesis, the surrounding bone is highly 
active and shows enhanced bisphosphonate uptake, calling into question the need for local 
delivery from coated implants.  
Authors: Some patients requiring orthopedic implants are likely to have osteoporosis. 
Regarding these patients: in cases of undiagnosed and untreated disease, a zoledronate-coated 
implant would certainly offer benefits compared to uncoated implants, as indicated by the 
present pilot study. In cases of patients already treated with bisphosphonate, there is no 
experimental evidence that zoledronate-coating would provide a better fixation than a 
systemic administration. However, while zoledronate-coating provides an immediate release 
of a very small amount of drug at the desired location (which in this case is independent of 
the rate of activity of the surrounding bone), systemic treatment provides a continuous drug 
uptake on a long-term basis. Thus, the optimal implant fixation in patients with osteoporosis 
may be obtained by a combined approach of local and systemic treatment, rather than one or 
the other, taking advantages of both approaches. However this hypothesis has yet to be 
experimentally demonstrated. 
 
Reviewers: This small paper suggests the possibility that local bisphosphonates can improve 
osseointegration of implants. Do authors have any estimate on the duration of such a positive 
effect? 
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Authors: Our objective was to obtain an increase of fixation at short-term. Indeed, clinical 
data suggests that a good short-term implant fixation is generally followed by a strong long-
term fixation, when compared to implant with early loss of fixation. Based on these results, 
we believe that the benefit observed after 4 weeks should last for much longer.  
But the duration of the beneficial effect depends on many factors such as the mechanical 
environment and the rate of elimination of the drug, thus the exact duration remains to be 
determined experimentally.  
 
Reviewers: As bone loss in the ovine osteoporosis model can be influenced by breed, season, 
diet etc, the omission of any data to confirm the extent of the osteopenia/osteoporosis in these 
3 animals is a concern. This could have been partially addressed by using each animal as its 
own control with a zoledronate coated implant in one femur and an uncoated control implant 
on the contralateral side – I doubt whether there would have been any systemic drug exposure 
from the coated implant. 
Authors: Strictly speaking the condition of these animals is osteopenia (based on BV/TV 
standard deviations) but the severe bone loss of 30% detected in illiac crests biopsies suggests 
that this model is comparable to osteoporosis condition in some human bones.  
Indeed, when planning the study, our concern was that the drug could influence the contra-
lateral side bone density, that is why we didn't use each animal as its own control. At 
posteriori, the extent of the effect of the drug is very limited (400?m) and thus there would 
certainly be no systemic effect. This supports the own-control design in the future. 
 
Reviewers: The reduced bone volume / trabecular volume is taken as an osteoporotic model 
of osteoporosis. Is this really a model of osteoporosis or osteopeania? Do the authors think 
that any sheep model is actually a realistic model of osteoporosis or more of osteopeania?        
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Authors:  To be exact the presented data is a model of severe osteopenia. There are actually 
no animal models that realistically reflect the human condition of osteoporosis. However, to 
our knowledge the OVX sheep model is the best model available to study orthopedic 
applications in osteoporotic bone (see Turner 2002).  
 
Reviewers:   Long term bisphosphonates have been seen to increase cortical bone thickness 
in elderly osteoporotic patients, yet recently it has been observed that this new cortical bone is 
very brittle and if fractured, very difficult to repair. I assume this is because the natural 
remodeling is knocked out by the bisphosphonates and the osteoclasts no longer function. 
What effect would local bisphosphonates have on the quality of the osseointegrated bone 
formed?  
Authors:  In the case of patients not exposed systemically to bisphosphonate in parallel to the 
presented technique, we don't think the quality of the bone is an issue on a long term 
perspective: the coated dose is available in the bone only once and is slowly retrieved from 
the coating and from the surrounding bone with normal metabolic processes. Therefore the 
remodeling of the periprosthetic bone should be reactivated after some time, and the damaged 
bone renewed. 
 106 
7  Paper 4: 3D strain map of axially loaded mouse tibia:  
a numerical analysis validated by experimental 
measurements 
 
Vincent A. Stadelmann, Jean Hocké, Jensen Verhelle, Vincent Forster, Francesco Merlini, 
Alexandre Terrier, Dominique P. Pioletti* 
 
Laboratory of Biomechanical Orthopedics EPFL-HOSR, Institute of Translational 
Biomechanics, Ecole Polytechnique Fédérale de Lausanne, Switzerland 
 
Accepted in Computer Methods in Biomechanics and Biomedical Engineering, in press 
 
*Corresponding author:  
Dominique P. Pioletti, Ph.D. 
Laboratory of Biomechanical Orthopedics EPFL-HOSR 
Station 15 
EPFL 
1015 Lausanne 
Switzerland 
Tel: +41 21 693 83 41 
Fax: +41 21 693 86 60 
Email: dominique.pioletti@epfl.ch 
 
 107 
Abstract 
A combined experimental/numerical study was performed to calculate the 3D octahedral 
shear strain map in a mouse tibia loaded axially. This study is motivated by the fact that the 
bone remodeling analysis in this in vivo mouse model should be performed at the zone of 
highest mechanical stimulus to maximize the measured effects. Accordingly, it is proposed 
that quantification of bone remodeling should be performed at the tibial crest and at the distal 
diaphysis. The numerical model could also be used to furnish a more subtle analysis as a 
precise correlation between local strain and local biological response can be obtained with the 
experimentally validated numerical model. 
 
Keywords:  
mechanical loading, bone remodeling, strain quantification 
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Introduction 
In vivo mechanical loading models have been developed to study mechano-transduction, 
which is the process of biological response to a mechanical stimulus. In particular for bone, 
the biological response to an applied external mechanical stimulus is generally quantified by 
morphological imaging (micro-computed tomography, scanning electron microscopy), 
histology or biomechanical tests (three or four point bending).  
Rubin et al. were pioneers in this field showing that cortical bone mass and size of the turkey 
ulna was regulated by mechanical stimulations (Rubin et al. 1996, Rubin and Lanyon 1984). 
Since this work, different studies were performed confirming the responsiveness of bone to 
mechanical stimulus. For example, Chow et al showed that mechanical loading is a 
determinant for the physiological behavior of cancellous bone in a rat vertebrae model 
(Chambers et al. 1993, Chow et al. 1993). More recently, non-invasive models of mechanical 
loading were adapted to the challenging dimensions of mice bones. Cyclic four-point loading 
were applied on mouse tibia and the results highlighted the difference in response between 
different breeds of mice (Akhter et al. 1998). Tibial axial loading was used to study site-
specific remodeling response to mechanical stimuli (De Souza et al. 2005, Fritton et al. 2005) 
and the loading effect on bone healing (Gardner et al. 2006).  
In vivo loading experiments require a precise control of the mechanical stimulus to correctly 
interpret the measured changes of the bone structure. It is likely that the most relevant 
structural changes of the loaded bone will be observed at the maximally stimulated locations. 
Therefore, to optimize the significance of a study, the choice of the location where 
histological or histomorphological imaging is to be processed should be defined in function of 
the spatial distribution of the mechanical stimulus. 
The most accessible measure of the mechanical stimulus is the strain. The strain variable has 
indeed been used in many different bone adaptation models (Carter 1987, Huiskes et al. 1987) 
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In this study, we want then to estimate the 3D strain map in an axial loading model of the 
mouse tibia. 
The mouse tibia is neither homogenous nor axisymmetric. Therefore the maximum strain 
location is not known a priori when an external load is applied. In order to assess the spatial 
distribution and intensity of strain in an axially loaded mouse tibia, we designed a study based 
on three steps. The first step was to experimentally measure the strain occurring at three 
different locations on a mouse tibia under different axial loads. In the second step, a 
numerical biomechanical model of a mouse tibia was built and validated with the 
experimental data. In the third step, the numerical model was used to extrapolate the strain 
distribution over the whole tibial geometry and to determine the 3D octahedral shear strain 
map and the highest strain locations.  
 
Materials and Methods 
In this section we will first describe the experimental procedure of measuring the strain at 
three different locations on the mouse tibia, followed by a description of the numerical model 
developed to quantify the strain on the whole mouse tibia.  
 
Animals 
C57BL6 male mice were acclimated to our facility for three weeks. They were maintained 
under standard no barrier conditions and had access to mouse chow and water ad libitum. The 
local ethics committee on animal care approved all animal procedures (Protocol#1920).  
 
Strain measures 
Nine mice were sacrificed at the age of 15±3 weeks, and the tibias were immediately 
extracted. Soft tissues were removed and the tibias were cleaned with acetone. The tibias were 
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separated randomly into three groups of six corresponding to three zones of tests on the tibia; 
zone 1: antero-proximal; zone 2: antero tibial crest; zone 3: postero-distal (Figure 1).  
 
 
Figure 1: Definition of the regions of interest on the mouse tibia. Zone 1, proximal tibia, 
presents a flat and regular surface. It is the widest area of the tibia; therefore the easiest 
location to place a gage. Zone 2 begins at the tibial crest and ends 1mm before the junction 
with the fibula. This zone is relatively flat but narrower than zone 1, therefore the strain gage 
is harder to place. Zone 3, distal tibia, is narrow and curved. It is the hardest surface to fix a 
gage. 
 
Each tibia received a single element foil strain gage (EA-06-015LA-120, Vishay Micro-
Measurements, Raleigh, NC, USA) aligned with the long axis bond to the bone surface with 
cyanoacrylate (Rapid Mix 72771, Forbo CTU, Schönenwerd, Switzerland). The gage was 
connected to a tension amplifier and digital recorder (DAQ NI9215, National Instruments, 
Switzerland). To verify the linkage between the strain gage and the bone surface, two tibias 
were scanned by micro computed tomography (?CT) at 9?m pixel size. The images showed 
that the gage location corresponded to the target and that no space was left between the gage 
and the bone surface (Figure 2).  
 
 111 
 
Figure 2: (a) Side-view of a ?CT scan of a tibia with a strain gage placed at Zone 2 and 
connecting wires. (b) Profile view along dotted line showing the strain gage linkage to the 
bone follows the contour of bone surface. 
 
Calibration of the setup 
A strain gage was placed at the center of an aluminum beam of dimensions 3 ? 10 ? 350mm 
and connected to the electronics. One end of the beam was fixed and controlled while loads 
were applied on the opposite end. The resulting tension was recorded for each load. To obtain 
the deformation-tension relationship, the beam deformation theory was applied to calculate to 
exact deformation at the center of the beam for each load.  
 
Mechanical loading 
A compression machine was developed to apply controlled compression cycles on mouse 
tibias, based on a previously published work (De Souza, Matsuura, Eckstein, Rawlinson, 
Lanyon and Pitsillides 2005, Fritton, Myers, Wright and van der Meulen 2005). Custom 
molded pads were placed on the axes to apply the compression on the bone ends. The tibia 
was then placed on the stimulation machine between the moving pad on the proximal-side 
and the fixed pad on the distal-side  (Figure 3). 
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Figure 3: (a) Tibia with strain gage fixed in zone 2. (b) Tibia placed in the loading machine 
with strain gage in zone 2. 
 
To maintain the initial position of the tibia, a pre-load of 0.2 N was applied before the 
dynamic compression. The compression waveform was composed of square like cycles at 
2Hz of frequency, and amplitude from 1N minimum force during 0.25s followed by maximal 
force during 0.25s. The maximal force increased from 1N to 10N by steps of 1N every 20 
cycles (Figure 4). Because of the natural curvature of the tibia, this simple axial loading 
induced combined compressive and bending strains. 
 
 
Figure 4 - Loading signal waveform with a frequency of 2Hz and maximum intensity at 8N for 
two consecutive loading cycles 
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Numerical model 
Geometry 
The geometry of a fresh specimen of mouse tibia was reconstructed from ?CT scan data 
(?CT40, Scanco Medical AG, Switzerland) at a 9?m resolution. The axial reconstructed 
images were then imported in AMIRA (Mercury Computer Systems, MA, USA) for the 
segmentation of the tibial bone volume. Finally, a geometric model based on parametric 
surfaces was built from the Amira data using Geomagic (Geomagic, Inc., NC, USA). 
 
Three-dimensional FE model 
The geometric model of the tibia was then imported into Abaqus (Simulia, RI, USA). A total 
number of 26,000 three-dimensional (20-node quadratic brick, reduced integration) elements 
were used to mesh the tibia. 
Material properties 
The density of the cancellous and cortical bone can vary greatly in the tibia. To incorporate 
this parameter, the Hounsfield number was correlated to the bone density. The Young’s 
modulus was then estimated using the equation derived by J.Y. Rho for a longitudinal 
compressed human tibia bone (RHO et al. 1995). 
Boundary Conditions 
Each of the articular end surfaces of the tibia were rigidly connected to a point placed at the 
center of the surface. The distal point was completely fixed while the proximal point was free 
to translate in the axial direction. An axial compressive force of 8N was applied on the 
proximal point.  
Measurements 
Strains were calculated in the direction of the experimental strain gauge, within the three 
locations (surface of bone) of the strain gauges. An average and standard deviation of the 
calculated strain was then obtained for each location. 
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Results 
Experimental strain  
At loading application, the strain has a peak of ~10% of the total strain and then drops to its 
plateau value until load is retrieved (Figure 5.a). The following measurements were recorded 
at plateau values. 
The force-strain relationship was established by successively increasing loading cycles 
between 1N and 10N for each zone. The force-strain relationships are linear with R2>0.95 for 
each zone (Figure 5.b).  
 
 
Figure 5: (a) Strain records at Zone 2 for a dynamic load of 8N for two consecutive loading 
cycles. (b) Force - strain experimental relations measured at three zones with the respective 
linear regressions and R
2
 values. 
 
For the 8N loading, the experimental values of the strain were 440±31?? at zone 1, 
1337±100 ?? at zone 2 and 444±81?? at zone 3. The strain values were significantly higher 
in zone 2 compared to zone 1 and zone 3.  
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Numerical model validation 
For 8N loading, the numerical values of the strain were 472±225?? at zone 1, 1320±372?? at 
zone 2 and 420±127?? at zone 3. These results correspond to experimental measurements 
with an error smaller than 10% (Figure 6). 
 
Extrapolation to the entire tibia, highest strain location 
The octaedral shear strain distribution was calculated numerically for five different locations: 
proximal tibia, proximal-diaphysis, tibial-crest diaphysis, midshaft and distal tibia (Figure 7). 
Mean octaedral shear strain was calculated for each zone on the antero and the postero side 
(Table 1). The maximal octaedral shear strain was found at the postero-tibial crest 
(1800±40??) and the antero-distal tibia (1940±30??). 
 
 
Orientation 
Proximal  
tibia 
Proximal  
diaphysis 
Tibial  
crest 
Midshaft  
Tibia 
Distal 
Tibia 
Antero 250±5 280±6 380±10 670±20 1940±30 
Postero 330±7 1050±20 1800±40 1400±15 640±20 
 
Table 1: Mean±SEM octaedral shear strain [??] for each orientation of each of the five zones   
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Figure 6: Distribution of the microstrains Ezz within each of the three measurement zones, 
relative to a locally defined coordinate system where the z-axis (arrows) is oriented along of 
the measurement axis and the y- axis is parallel to the measurement plate. Comparisons with 
experimental data are shown in the right column for each zone at different loading intensities. 
The relative differences are smaller than 10%. 
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Figure 7: Octahedral shear strain distribution calculated numerically for five different 
locations: proximal tibia (a), proximal-diaphysis (b), tibial-crest diaphysis (c), midshaft (d) 
and distal tibia (e). Lines represent antero/postero separation and values represent the mean 
octahedral shear strain in the respective zone. 
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Discussion 
Although bone adaptation to mechanical environment has been observed for decades, the 
mechanisms underlying the perception of the mechanical stimulus by the cell and the 
biological pathways of the cell response are still far from being completely understood. 
The in vivo mechanical stimulation of mice tibias combined with histology and 
histomorphometry (?CT) is certainly one of the most promising techniques to gain further 
understanding in the bone remodeling answer to mechanical stimulation. However, histology 
and ?CT are both very time-consuming techniques, and therefore these techniques are 
generally used only at few locations of the tibia (generally the midshaft, proximal and distal 
sections), regardless of the loading state.  
The goal of this study was to estimate the 3D map of the octahedral shear strain distribution 
within the tibia of a mouse under specific axial loading that corresponds to our experimental 
setup. Octahedral shear strain intensity is a good approximation of the mechanical stimulus 
that cells can sense (Terrier et al. 1997). Thus, the 3D strain map will serve as a reference for 
our future histology and ?CT planning, and it might as well be useful to any similar axial 
stimulation experiments.  
To determine the 3D map of the octahedral shear strain distribution within the loaded tibia, a 
finite-element model of a mouse tibia was built from ?CT images. The model was first 
validated with ex-vivo experimental measurements of strain at three different locations on 
loaded tibias. Then the model was used to extrapolate these values to the entire tibial volume.  
The maximal octahedral shear strain, calculated on the volumic model, was found at the 
postero-tibial crest (1800±40??) and the antero-distal tibia (1940±30??). These results 
indicate that bone remodeling should be quantified in these areas, either for histological or 
histomorphological measurements, as a maximal mechanical stimulus will generate a 
maximal response of the tissue. It should be noted however, that even in the maximal strain 
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zone, differences in strain values exist inside the tibial section. A precise correlation between 
applied external mechanical stimulus and biological response can then be obtained only by 
using the combined approach (experimental/numerical) followed in this study.  
The loading force-local strain relationship was shown to be linear in the three experimental 
zones until at least 1500?? strain. Using a comparable loading system, the experimental strain 
values are in accordance (max 6% difference) with De Souza et al. (De Souza, Matsuura, 
Eckstein, Rawlinson, Lanyon and Pitsillides 2005). Our experimental set-up can then be 
considered as validated. 
When experimental and numerical strain values were compared, a maximum difference of 
10% was found for the three different zones. These differences can certainly be considered as 
acceptable, thus validating the numerical model. It should be mentioned that the results of the 
numerical model should be carefully considered for the very proximal and very distal part of 
the tibia as the joint surface and the underlying trabecular bone might affect the numerical 
results. However, as the maximal strain is not found in these two regions, this aspect does not 
invalidate the determination of the maximal strain zone. 
A limitation for the correlation process between external load and biological response is 
related to the fact that loads were applied in the axis of the tibia, inducing combined axial 
compressive and bending strains due to the natural curvature of the bone. These different 
modes of strain were not accounted for in the presented analysis. Strictly from a 
biomechanical point of view, it is interesting to note that the numerical model indicated that 
the maximum bending was observed on the fibula. However, this information is of limited 
practical use as this bone is too small to place a gage to confirm the numerical result. 
Moreover, this tissue is also too small for histology or histomorphometry analysis. 
In this study, we assumed that the mechanical stimulus is directly related to strain. In the 
literature, different mechanical stimuli have been proposed to explain bone remodeling 
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(Huiskes et al. 2000, Parfitt 1996, Prendergast and Huiskes 1994, Turner and Pavalko 1998). 
However, from an experimental point of view, only the tissue elongation transformed to a 
strain value is accessible. Other mechanical stimuli are mathematically related to the strain 
through constitutive laws. The calculated zone of highest strain obtained in this study can also 
be of general use for models using different descriptions of the mechanical stimulus. 
To conclude, an experimental/numerical approach has been developed to identify the 3D 
octahedral shear strain map in an axial loading mode for a mouse tibia. It is proposed that 
quantification of bone remodeling should be performed at the tibial crest and at the distal 
diaphysis as the maximum biological response should correspond to the maximal applied 
strain. The numerical model could also be used to furnish a more subtle analysis as a precise 
correlation between local strain and local biological response can be obtained. 
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Abstract 
Local bisphosphonate delivery may be a solution to prevent periprosthetic bone loss and 
improve orthopedic implants fixation. In load-bearing implants, periprosthetic bone is 
exposed to high mechanical demands, which in normal conditions induce an adaptation of 
bone. In this specific mechanical situation, the modulation of the bone response by 
bisphosphonate remains uncertain. 
We assessed the combined effects of zoledronate and mechanical loading on bone adaptation 
using an in vivo axial compression model of the mouse tibia and injections of zoledronate. 
Bone structure was assessed with in vivo ?CT before and after the period of stimulation and 
the biomechanical properties of the tibias were assessed with 3point-bending tests after 
sacrifice. Axial loading induced a localized increase of cortical thickness and bone area. 
Zoledronate increased cortical thickness, bone perimeter, and bone area. At the most loaded 
site of the tibia, the combined effect of zoledronate and mechanical stimulation was 
significantly smaller than the effect of zoledronate plus the effect of mechanical loading. This 
suggested that an interaction between zoledronate and mechanical loading might exist at high 
levels of strains. 
 
Keywords 
Bone adaptation; In vivo mechanical loading; Bisphosphonate; Zoledronate; In vivo ?CT   
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Introduction 
Periprosthetic bone loss facilitates the occurrence of aseptic loosening. Periprosthetic bone 
loss is initiated at the very early stage after an implant is set. Different authors have suggested 
the solution of local bisphosphonate release from the orthopedic implant to prevent the bone 
resorption at this early post-operative stage [1, 2]. It has been shown that local 
bisphosphonate preserves periprosthetic bone stock, in rats and sheep [3-5] and also increases 
the fixation strength, in rats [4, 6]. In these studies the implants were not specifically loaded 
mechanically, in contrary of the clinical situation of load-bearing implants, where the 
periprosthetic bone is exposed to high mechanical demands [7]. In this specific mechanical 
situation, the modulation of the bone response by bisphosphonate remains uncertain. 
 
Bone can adapt to mechanical demands. This process involves osteocytes, cells that sense 
mechanical stimulations, osteoclasts that resorb bone, and osteoblasts that form new bone. 
Bone adaptation relies upon the communication between these cells, through cell-cell contacts 
and local cytokines [8-11].  
Bisphosphonates inhibit osteoclasts differentiation and activity, consequently they slow down 
the bone turnover rate. Given the constant communication between the bone cells, the 
changes that affect one type of cells has indirect consequences on the other types of cells. In 
the specific case of periprosthetic bone this could lead to an unwanted pathological response.  
 
The aim of the present study was to assess the effect of zoledronate, the newer member of the 
third generation bisphosphonates [12-14], on bone adaptation to mechanical loading in order 
to anticipate pathological outcomes when using it in highly loaded bone structures. For this 
purpose, we used an in vivo axial compression model of the mouse tibia [15, 16] and analyzed 
the effect of zoledronate on site-specific bone adaptation.  
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Materials and Methods 
Animals 
Eleven C57BL6 male mice, 17±1 weeks old, were acclimated to our facility for three weeks. 
Mice were caged in groups of three or four. They were maintained under standard no barrier 
conditions and had access to mouse chow and water ad libidum. The local ethics committee 
on animal care approved all animal procedures (Protocol#2006.1).  
The mice were separated randomly into two groups: on day 0, the five animals of the 
zoledronate group received a single subcutaneous injection (80 ?l) of 1 ?g/kg zoledronate  
(Novartis Pharmaceuticals AG, Switzerland) while the six animals of the control group 
received an equivalent injection of saline. 
 
Anesthesia 
General anesthesia was induced with a ketamine (80 mg/kg) and xylazine (5 mg/kg) cocktail 
administered intraperitoneally unless specified. 
 
?CT 
We assessed trabecular and cortical bone architecture using in vivo micro-computed 
tomography (μCT1076 in vivo, SkyScan, Belgium), at day 0 and day 11.  
Animals were anesthetized. The lower limbs were fixed in a custom polystyrene support and 
aligned with the axis of rotation of the scanner. The tibias were then scanned with 9-μm 
isotropic voxel size, 50kV beam, 0.8° step rotation. Reconstructions and analysis were 
performed with built-in routines of manufacturer’s softwares NRecon and CTan, following 
the standard protocols. The reconstructed tibia contained about 1900 slices. 
Trabecular thickness (Tb.Th) was evaluated at the proximal tibial metaphysis, whereas 
cortical thickness (Ct.Th), bone perimeter (B.Pm) and bone area (B.Ar) were evaluated at four 
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different locations of the diaphysis: zones 1 and 2: 150 slices of the proximal diaphysis at 1/5 
and 2/5 of the tibial length respectively; zone 3: 150 slices at the midshaft; zone 4: 150 slices 
of the distal diaphysis at 4/5 of the tibial length (Figure1a). Zone 1 was then divided in four 
sub-regions of interest, corresponding to the four facets, to assess orientation specific 
remodeling (Figure1b). 
 
 
Figure 1 - Regions of interests. (a) Definition of the five ROIs: proximal for trabecular bone 
and zone 1 to 4 for cortical bone. (b) Definition of the 4 sub-regions of zone 1. 
 
In vivo compression 
A compression machine was developed to apply controlled compression cycles on the tibias, 
based on a previously published work [15, 16]. On day 1, 3, 5, 8 and 10 the left tibia of all 
animals were mechanically stimulated with dynamic axial compression sequences. Custom 
molded pads were designed on the axes ends to apply the compression on the leg. 
Each animal was anesthetized and placed on a warm support with eye gel until completely 
unresponsive. The animal was then placed on the stimulation machine with the left leg 
between the moving pad on the knee and the fixed pad on the ankle  (Figure 2a). 
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To maintain the initial position of the leg, a pre-load of 0.5 N was applied before the dynamic 
compression. The compression waveform was composed of square like cycles at 2Hz 
frequency, and amplitude from a force of 0.5 N during 0.25s followed by a force of 8N during 
0.25s (Figure 2b).  
 
 
Figure 2 - (a) Animal’s left tibia placed in the compression machine between the molded 
cups. (b) Compression waveform. 
 
The sequence of compression was applied during 1 min. Then the animal was placed at rest 
on the warm support. After 15 min a second sequence of 1 min of dynamic compressions was 
applied. Then the animal was placed on the warm support until it moved. 
Because of the natural curvature of the tibia, this simple axial loading induced combined 
compressive and bending strains. Axial compression of 8N induces maximum octahedral 
shear strain at the postero-tibial crest (1800±40??) and the antero-distal tibia (1940±30??) 
[17].  
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Sacrifice and tibias extraction 
On day 11, while still under anesthesia for the ?CT, the animals were sacrificed with an 
overdose of ketamin.  Both tibias were extracted surgically and placed in wet conditions at 
4 °C. 
 
Mechanical tests 
Tibial biomechanical properties were assessed by 3-point bending [18, 19], using the Instron 
Microtester 5848, (Instron, MA, USA) equipped with a 100 N gauge and custom bone 
supports. The fibula was removed with a surgical blade before the tests. The lower supports 
distance was set to 12mm for all tibias, and the tibias always placed proximal end to the left 
and up, distal on the right. The crosshead speed was set to 0.02 mm/s and the force-
displacement data sampling to 100 Hz.  
The ultimate force, stiffness and postyield energy to failure were calculated from the collected 
data. The yield point was defined by using a 0.3 N offset from the stiffness line [20].  
 
Analysis 
Data is generally presented as Mean±SD and all statistical procedures were performed with 
Mathematica5® (Wolfram Research, USA). The number of tibias per group was accounted 
for as repetition of the measurement. Effects of mechanical loading and zoledronate were 
analyzed with two-way ANOVA and Tukey posthoc-tests. For independent data, Student-t 
test was used to determine the statistical power of the difference: p<0.05 was considered 
significant and, given the small number of animals per group, p<0.1 was considered as a 
strong trend. 
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Results 
Twenty-two tibias were analyzed in this preliminary study (Table 1). In the control groups, 
two animals could not be scanned on day 0; they were excluded from follow-up data. Two 
tibias were damaged during extraction; they were excluded from biomechanical analyses.  
 
 force 
zoledronate 0N (right) 8N (left) 
no 6 6 
yes (1?g/kg s.c.) 5 5 
Table 1 - Number of tibias in each group 
 
Effect of mechanical loading and zoledronate on biomechanical parameters  
Mechanical loading significantly enhanced the tibial stiffness by 16% compared to control, 
but had no effects on ultimate force and postyield energy to failure. Zoledronate significantly 
increased the stiffness, ultimate force and postyield energy to failure by 31%, 24% and 60% 
respectively, compared to control group. The effect of zoledronate on all three biomechanical 
parameters was significantly higher than the effect of mechanical loading alone. 
Mechanical loading combined with zoledronate significantly increased the biomechanical 
parameters, compared to control tibias. This effect was significantly higher than the effect of 
mechanical stimulation alone on ultimate force and postyield energy to failure. However, no 
significant difference was observed between the effect of zoledronate and the combined effect 
of mechanical loading and zoledronate (Figure 3).   
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Figure 3 - Biomechanical parameters for each group. F>0 indicates mechanically stimulated 
groups. Z=yes indicates zoledronate groups. Arrows indicate groups with significant 
differences (p<0.05).   
 
Finally, for the three biomechanical parameters, the sum of the effect of mechanical loading 
and the effect of zoledronate was not significantly different than the effect of mechanical 
loading and zoledronate. Note that no effect was detected on paired comparison of the 
biomechanical parameters due to the loss of a tibia in the control group. 
 
Effect of mechanical loading and zoledronate on histomorphometric parameters 
When analyzing the evolution of individual tibias between day 0 and day 11 (Figure 4), we 
observed that mechanical loading alone induced a significant increase of 20% of Ct.Th in 
zone 1c compared to control tibias, and the increase of 9% and 12% in zones 1 and 2 
respectively was a strong trend (p<0.1).  Mechanical loading also induced a significant 
increase of B.Ar of 10% in zone 1. Mechanical loading had no significant effect on the 
evolution of B.Pm and Tb.Th in all zones.  
Zoledronate treatment alone had no significant effect on the evolution of histomorphometric 
parameters. Zoledronate treatment combined with mechanical loading induced a significant 
increase of Ct.Th of 15% compared to control in zone 1d. 
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In zones 1 and 1b, mechanical loading had a significantly greater effect on Ct.Th than the 
zoledronate treatment.    
Surprisingly, when analyzing pooled groups of tibias (Figure 5), we observed a different 
pattern of response: Ct.Th in zone 1c of mechanically loaded tibias was significantly greater 
by 10% compared to controls, but no differences in other zones were observed.  
Ct.Th of tibias treated with zoledronate alone was significantly greater than controls by 10% 
in zone 4 (p<0.05), and we observed a trend of the same difference in zone 3 (p<0.1). In zone 
1, 2, 3 and 4, B.Ar of tibias treated with zoledronate was significantly greater by 12%, 15%, 
15% and 15% respectively compared to controls.  
Tibias with zoledronate and mechanical loading had significantly higher B.Ar in all zones 
compared to controls and mechanically stimulated ones. However these tibias were not 
significantly different that zoledronate-treated tibias.  
Finally in all zones except zone 1c, the effect of combined zoledronate and mechanical 
stimulation was equivalent to the sum of the effect of zoledronate and the effect of 
mechanical stimulation. In zone 1c, the effect of combined mechanical stimulation and 
zoledronate was significantly different than the sum of the effects. 
 
Discussion 
Local bisphosphonate release may be a solution to prevent periprosthetic bone loss and 
improve the implant fixation. However, in the case of load-bearing implants, periprosthetic 
bone is exposed to high mechanical demands, which in normal conditions induce an 
adaptation of bone. When zoledronate is present in bone, it alters its local metabolism. The 
aim of the study was to assess interactions between mechanical loading and zoledronate on 
bone adaptation in an in vivo stimulation experiment.  
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We observed that axial mechanical loading induced a localized increase of cortical thickness 
and cortical bone area. These site-specific changes are concordant with previous studies [15, 
16]. Animals treated with zoledronate had site-specific increased of cortical thickness and 
cortical bone perimeter. The cortical bone area was increased in all zones, which is 
concordant with previous studies [21-23]. 
 
Figure 4 - Evolution of histomorphometric parameters of individual tibias from day 0 to 
day 11 in % change. Arrows indicate groups with significant difference (p<0.05). 
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Figure 5 - Effect of mechanical loading (F>0) and zoledronate (Z=y) on histomorphometric 
parameters. Arrows indicate significant difference (p<0.05) between groups, while dotted 
lines indicate strong trends of difference (p<0.1). 
 
In most cases, the effect of combined zoledronate and mechanical stimulation was equivalent 
to the sum of the effect of zoledronate and the effect of mechanical stimulation. However in 
zone 1c, the effect of combined zoledronate and mechanical stimulation was significantly 
smaller than the sum of the effects.  
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Using experimental measures and numerical simulations, we previously showed that during 
axial compression, bone in zone 1c undergoes the highest strain levels (about 1900?? for 8N 
load) while the rest of the tibia is less loaded. The specific results in zone 1c suggest that an 
interaction might exist between the bone response to mechanical stimulation and the effect of 
zoledronate at high levels of strains.  
The decreased effect of combined mechanical stimulation and zoledronate compared to 
mechanical stimulation alone, might reflect an upper limit on bone adaptation rate induced by 
the zoledronate when mechanical stimulations reach a high intensity.  
This result can seem to be contradicting previous studies that have assessed the impact of 
bisphosphonate on bone response to mechanical demands. As examples, Jagger et al. have 
shown that, in rats caudal vertebrae exposed to mechanical stimulus, the rate of bone 
apposition is not affected by bisphosphonate [24]. Braith et al. have shown that bone loss can 
be prevented by alendronate treatments and that alendronate combined with mechanical 
loading induced a gain of bone mass9. However, in these studies the strain levels were in the 
range of physiological loadings.  In this range of strains (all zones except zone 1c), our data 
concord with the cited results. To our knowledge, no other data exists assessing the effect of 
bisphosphonate in over-physiological mechanical conditions.  
 
This preliminary study intended to reveal possible interactions between zoledronate treatment 
and mechanical stimulations. It was therefore based on a reduced pool of mice. The 
hypothesis that the interaction appears in response to high strain condition cannot be verified 
with the present data. To verify this hypothesis, a regression study with different intensities of 
mechanical loading will be performed with a larger pool of mice. 
                                                
9 this study was performed in the specific situation of bone loss associated to corticoid treatment 
following lungs transfer. 
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The possible limitation of the bone response to high mechanical stimulations by zoledronate 
would require a specific design of load-bearing implants, to prevent drug accumulation in 
high-loading areas of the periprosthetic bone. 
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Conclusion and perspectives 
The long-term durability of total joint replacements depends critically on the preservation of 
periprosthetic bone stock. The bone stock can be compromised by micromotions and 
accumulation of debris wears, but the precise chronology of biological events that finally 
leads to a critical bone loss had not been determined yet. More insights of this chronology and 
of the biological role of micromotions would certainly provide valuable information toward 
the development of therapeutic solutions.  
 
Early effects of micromotions 
The first aim of this thesis project was therefore to assess the effect of micromotions on 
human bone at the cellular level. For this purpose, we applied micromotions on top of fresh 
human bone cores ex-vivo. We measured that one hour of micromotions increases the 
activation signal of osteoclasts (RANKL/OPG) by 24-fold [24].  This unique human data 
suggests that micromotions are the initiators of the early periprosthetic bone loss. In other 
words, early periprosthetic resorption is the rapid response of bone cells to a local stimulus, 
the micromotions. Thus, to prevent early bone loss, a local solution, such as local 
bisphosphonate release, seems more appropriate than a systemic approach!  
 
Local release of bisphosphonate 
The efficiency of the local bisphosphonate solution was already supported by a few in vivo 
studies [106, 111-113], however these studies had two major limitations: first, the design was 
mainly empirical, and second, they were only performed with rats.  
To design future animal or clinical studies and to compare their outcomes, there was a need 
for a comprehensive model of bone adaptation in the specific conditions of local diffusion of 
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bisphosphonate. The second aim of this thesis was therefore to develop a mathematical model 
of periprosthetic bone adaptation around implants releasing bisphosphonate. The model that 
was developed updated a mechanically-driven bone adaptation model by adding an equation 
of drug-driven bone adaptation and a drug diffusion law. The identification of the model 
parameters was carried-out with existing data of zoledronate local release in rats. Based on 
the updated model, the dose of zoledronate that would maximize the periprosthetic bone 
density was predicted; this prediction was then confirmed in vivo with a good accuracy.  
Complementary data in a big animal model was required to confirm the potential of the local 
bisphosphonate solution in human-like bone. Thus, the third aim of the thesis was to perform 
the necessary experiments to produce this complementary data. Using titanium implants 
releasing zoledronate in the trabecular bone of osteoporotic sheep, we measured that the 
periprosthetic bone was 50% denser with local zoledronate than without.   
  
Comparison of rats and sheep data 
Comparing the new sheep data to previous rats data provided interesting information about 
the possible extrapolation of the rat results to clinical perspectives. The sheep and rat data 
were compared within the developed theoretical framework. First, we tested the validity of 
the model in sheep: the bone density distribution, as calculated with the theoretical model10, 
fits the experimental bone density in sheep with a mean error smaller than 5% (Figure 17a). 
An interesting feature of the theoretical model is the “drug signature” that reflects the bone 
response to the drug in a specific animal model. This function is a measure of the local bone 
adaptation rate in response to the local drug concentration, in contrary to measurements of 
bone change in response to systemic administration, which strongly depend on the 
                                                
10 In this calculation, we assumed that the diffusion coefficient of the drug and the boundary 
conditions were the same as in the rat model.  
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bioavailability, the drug distribution and the local bone metabolism. These remarks highlight 
the potential use of the theoretical model as a convenient framework to compare experimental 
outcomes, and even, as a rationale for the design of future experiments.   
As an example, the signature function of zoledronate was calculated in sheep from the 
experimental data and compared to the signature function in rats obtained previously (Figure 
17b).  
 
Figure 17 - (a) In sheep, the model prediction (lines) fits the experimental bone density (dots) 
with a mean error smaller than 5%. (b) Zoledronate signature in rats and sheep.  
 
Although the signature in sheep is only available for two concentrations, it was striking to 
observe that the order of magnitude were comparable in the two species, at the same drug 
dose, despite the major differences in anatomy and metabolism. 
 
Bone adaptation to mechanical stimulus and zoledronate 
The fundamental assumption in the theoretical model was that the mechanical stimulus and 
the drug stimulus were independent, thus the effects of the two stimuli were simply summed 
up in the adaptation equation. However, as mentioned previously, the implants in rats and 
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sheep studies were not specifically loaded mechanically. Based on this experimental data, it 
was then not possible to formally confirm or reject the independence assumption.   
The last aim of the thesis was then to investigate the potential interactions between 
mechanical loading and bisphosphonate on bone adaptation. Using a model of the mouse tibia 
adaptation to axial compression, combined with systemic injections of zoledronate, we 
observed that the effects of each stimulus can be added in general, however in locations with 
very high strains, about 2000??, zoledronate seemed to reduce the bone adaptation rate, but 
this result remains to be confirmed with more data.  
If this effect was confirmed, the theoretical model would have to be update consequently with 
an interaction term. Nevertheless, as the effect was detected for very high strains, for most 
physiological values of strains, the model remains valid.    
 
Clinical relevance 
On a clinical perspective, the most meaningful results were, first, that a local and immediate 
mechanical process, micromotions, initiates periprosthetic bone resorption rapidly and thus 
favors aseptic loosening at long-term. This result provides a strong rationale for the local use 
of bisphosphonate rather than systemic. The second major result of the thesis was the 
demonstration that local bisphosphonate preserves periprosthetic bone stock in sheep. This 
result suggests that a preclinical study of total joint replacement with a bisphosphonate-coated 
implant can be performed in sheep, with good chances of success to demonstrate an increased 
fixation. Finally, although it is quite technical, the mathematical framework provides a useful 
tool to plan clinical studies and compare results. This framework could also be used to 
compare the performance of the different bisphosphonate in local applications. 
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